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1. Introduction 
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Cardiovascular diseases and in particular Chronic Heart Failure (CHF) 
represent one of the challenge to be faced by National Health System, 
because of their mortality and morbidity[2], related expenditure[3] and 
huge impact on health-related quality of life[4]. Limited health funding and 
rapidly expanding population of older patients with CHF are leading many 
National Health Services (NHSs) to search for new programs of care, 
which allows providing high-quality care in settings alternative to hospitals 
ones. Home-monitoring (HM) and Disease Management Programs (DMP) 
were widely explored in the last years because, compared to usual care, 
they can provide specialised care to a larger number of patients with a 
limited access to healthcare services. Moreover, both HM and DMP are 
effective alternatives to UC for management of CHF, reducing mortality 
and readmission rate[5]. A wide literature investigates their effects on 
clinical outcomes of patients suffering from CHF[5-14]. In almost the 
totality of study, those models have been compared to UC, and there is not 
sufficient literature comparing directly HM and DMP[15-17]. This 
comparison is needed since some National Health Services (NHSs), as the 
Italian one[18], are promoting the adoption of HM as an alternatives to UC, 
while preliminary studies proved that, although HM could be slightly more 
effective than DMP, HM is up to five times more costly than DMP[19], and 
therefore less cost-effective. Therefore, the first aim of the current thesis is 
to provide a systematic comparison of efficacy of HM benchmarked with 
DMP, which is reported in the chapter 1. Moreover, I contribute to the 
project and design of a telemedicine service enhanced with data-mining 
and pattern recognition. In the chapter 2, the design of the telemedicine 
platform is described and the details about the data-mining application for 
Heart Failure detection and assessment are reported. In the chapter 3, the 
results relative to a data-warehouse for hypertensive patients is reported. 
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Finally, the chapter 4 presents the results of the research for prediction of 
long-term survival in the elderly. 
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2. Model of care for Chronic Cardiac Patients  
 11 
2.1 Disease Management Programs 
Nowadays, Disease Management Programs (DMP) are considered valid 
alternatives to usual care for management of Chronic Heart Failure, 
reducing mortality and  readmission rate[5]. 
DMP[9, 21] are models of care which consist in coordinated and 
multidisciplinary healthcare interventions and communications for 
populations with conditions in which patient self-care efforts are 
significant. DMP are mainly oriented to five chronic diseases: ischemic 
heart disease, diabetess, COPD, asthma and heart failure. DMP generally 
include telephone calls, during which patients interact with trained nursing 
professionals, and require an extended series of interactions, including a 
strong educational regarding lifestyle. Patients and their relative are 
expected to play an active role in managing their diseases[22]. 
From a literature research (for details about the keywords adopted see 
section 2.3), 31 randomized clinical trials (RCTs) comparing DMP and 
usual care in patients suffering from CHF were identified. The most 
important information of these studies were reported in the Table 1 
 
Table 1: characteristics of the studies comparing Disease Management Programs 
with Usual Care 
Atienza F, 2004  
Participants 338 patients admitted with decompensated Heart Failure 
Mean age  68 (median) 
Male percentage 60% 
Country Spain 
Interventions  On admission, all patients with heart failure considered for 
inclusion were managed by the responsible cardiologist 
according to guidelines published at the time of designing the 
study. 
The intervention program consisted of three phases. In the first 
phase, the patients and their families received formal education 
about the disease. Prior to discharge, the research cardiac nurse 
had an in-depth interview with the patient and caregivers. 
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Atienza F, 2004  
Specifically, the nurse assessed the patient knowledge of the 
disease, the ability to identify signs and symptoms of heart 
failure worsening, and the most common responses to the 
situations of deterioration. This education session included 
explanations of symptoms and signs of heart failure 
decompensation, importance of self-monitoring of vital signs, 
diet and exercise counselling, effects of medications and 
importance of compliance, and measures to be taken in case of 
worsening. Individualized strategies were used to improve 
treatment adherence and to empower patients to manage health 
problems (i.e. diuretic self-adjustment). All this process was 
supported by using a teaching brochure developed by the study 
investigators. The patient was discharged home by the 
responsible cardiologist who prescribed treatment without 
knowledge of the assignment group. 
In the second phase, a visit with the primary care physician 
was scheduled within 2 weeks of discharge. The aims of this 
visit were to monitor patients’ clinical progress, identify 
incipient physical signs of decompensation, and reinforce the 
educational knowledge. When the patient showed clinical 
signs of worsening, the primary care physician was allowed 
either to modify the discharge treatment or to refer the patient 
to the hospital for reassessment.  
During the third phase, regular follow-up visits at the 
outpatient Heart Failure Clinic were scheduled every 3 months 
where, in addition to the routine clinical assessment, the 
cardiologist reviewed the patients’ performance and introduced 
correcting strategies to improve treatment adherence and 
response. This visit reinforced patients’ knowledge of the 
illness and increased their ability to manage health problems. 
The heart failure specialist coordinated visits to other 
specialists, diagnostic tests and treatments prescribed by other 
instances. The telemonitoring phase lasted from discharge until 
the end of the study and consisted of a facilitated telephone 
communication with a monitor (SCT), providing a 24-h mobile 
phone contact number. The heart failure clinic team was also 
available for consultation during working hours. Patients were 
instructed to contact the monitor or the heart failure team in 
case of doubts or signs of worsening. 
Control group patients received discharge planning according 
to the routine protocol of the study hospitals. To avoid 
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contamination of the control group management, additional 
follow-up was performed by primary care physicians and 
cardiologists not participating in the study.  
Outcomes Readmission, mortality, quality of life, cost 
Follow-up length  12 months 
Notes  
 
Blue L, 2001  
Participants 165 patients admitted with heart failure 
Mean age  75 years 
Male percentage 58% 
Country UK 
Interventions  Patients in the usual care group were managed as usual by the 
admitting physician and, subsequently, general practitioner. 
They were not seen by the specialist nurses after hospital 
discharge. 
The nurse intervention consisted of a number of planned home 
visits of decreasing frequency, supplemented by telephone 
contact as needed. The aim was to educate the patient about 
heart failure and its treatment, optimise treatment (drugs, diet, 
exercise), monitor electrolyte concentrations, teach self 
monitoring and management (especially the early detection 
and treatment of decompensation), liaise with other health care 
and social workers as required, and provide psychological 
support. The nurses were given training in these roles before 
the start of the study. They used written protocols on the use of 
angiotensin converting enzyme inhibitors, diuretics, and 
digoxin in chronic heart failure and liaised with members of 
the department of cardiology as required. Participants were 
given a pocket sized booklet containing an explanation of heart 
failure and its treatment; dietary advice; contact details for the 
heart failure nurses; a list of their drugs, weights, and blood 
test results; and details of planned visits (dates and times). 
Outcomes All-cause mortality, hospital admission for Heart Failure 
Follow-up length  12 months 
Notes  
 
Bouvy M L,2003  
Participants 152 patients with heart failure (predominantly New York Heart 
Association [NYHA] II and III) 
Mean age   
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Bouvy M L,2003  
Male percentage 66% 
Country The Netherlands 
Interventions  Cardiologists informed patients about the study. Patient’s 
pharmacy and general practitioner (GP) were notified of their 
participation in the study. Pharmacists received training for the 
intervention that consisted of a structured interview on the 
patient’s first visit to the community pharmacy after inclusion 
into study. A computerized medication history was used to 
discuss drug use, reasons for non-compliance — such as 
possible adverse drug reactions and difficulties to integrate 
medication use in daily life — to reinforce medication 
compliance. A short report of this interview was forwarded to 
the GP. Pharmacists then contacted patients on a monthly basis 
for a maximum of 6 months. Patients in the usual care group 
did not receive the structured interview or monthly follow-up. 
Outcomes Number of rehospitalizations, death, and quality of life, 
Follow-up length  6 months 
Notes  
 
Cline C M,  1998  
Participants 190 patients admitted with heart failure 
Mean age  76 years 
Male percentage 52.3% 
Country Sweden 
Interventions  First, patients and their families received an education 
programme on heart failure, describing its pathophysiology 
and pharmacological and non-pharmacological treatment. 
Adherence to prescribed medication was emphasised and 
patients were offered a seven day medication organiser 
(Dosett) if the study nurse considered one to be appropriate. 
Second, patients received guidelines for self management of 
diuretics based on the signs and symptoms of worsening heart 
failure (increased body weight, ankle oedema, dyspnoea, and 
fatigue) or fluid depletion (rapid weight loss). These data were 
registered in a patient diary (body weight, ankle 
circumference, and heart failure symptoms were regularly 
recorded). The education programme consisted of two 30 
minute information visits by a nurse during primary 
hospitalisation and a one hour information visit for patients 
and family two weeks after discharge. In-hospital information 
on pathophysiology and self management guidelines were 
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contained in the patient diary. The group information, held by 
a study nurse, employed an oral and video presentation to 
reinforce the information given in hospital. A special effort 
was made to inform family members who were present. Time 
was available for questions to the study nurse. Finally, patients 
were followed up at an easy access, nurse directed, outpatient 
clinic. The nurse was available by telephone during office 
hours and was able to see patients at short notice. There was 
only one prescheduled visit by the nurse at eight months after 
discharge. Patients were encouraged to contact the study nurse 
if: their diuretic adjustments did not ameliorate symptoms 
within two to three days; they felt unsure about which course 
of action to take; there were profound changes in self 
management variables; or at their discretion. 
The study nurses were registered nurses with experience of 
heart failure from coronary care units and clinical heart failure 
trials. They attended an overview lecture on heart failure 
before starting the study and were able to consult a cardiologist 
about specific patients at all times. They were also able to 
schedule doctors’ vvisits as they considered appropriate. 
Intervention patients were offered outpatient visits with 
doctors at the department of cardiology at one and four months 
after discharge.  
The control group was followed up at the outpatient clinic at 
the department of cardiology, by either cardiologists in private 
practice or primary care physicians as considered appropriate 
by the discharging consultant. The treating physician was free 
to evaluate or treat as appropriate. 
Outcomes Mortality, hospitalization 
Follow-up length  12 months 
Notes  
 
DeBusk R F,  2004  
Participants 462 patients hospitalised with a provisional diagnosis of CHF 
from Kaiser Permanente. 
Mean age  72 years 
Male percentage 51% 
Country USA 
Interventions  Standardised telephonic physician directed nurse-managed 
case management, involving CHF lifestyle education and 
medication management. Patients contacted weekly for 6 
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weeks, biweekly for 8 weeks and then monthly and bimonthly. 
Usual care not clearly defined, but was provided by the 
participating Kaiser Permanente medical centres, appeared to 
involve a high frequency of all of kinds of follow-up clinic 
visits (13 in 12 months following hospitalisation). 
Outcomes Mortality, rehospitalisation, emergency and outpatient 
department visits, prescription of recommended 
pharmacotherapy. 
Follow-up length  12 months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
DeWalt D A, 2006  
Participants 127 patients with confirmed HF, NYHA class II-IV symptoms 
within the last 3 months and currently taking furosemide from 
the University of North Carolina (UNC) General Internal 
Medicine Practice. 
Mean age  62.5 years 
Male percentage 47% 
Country USA 
Interventions  Intervention patients received self-care education, picture-
based educational materials with verbal explanation, a digital 
scale and scheduled follow-up phone calls (days 3, 7, 14, 21, 
28, 56) and monthly during months 3-6 for reinforcement of 
education and revision of individualised care plan. 
Control group patients received a general heart failure 
education pamphlet and usual care from their primary 
physician (not specified). Data collection occurred at 6 and 12 
months via in-person interview and medical record review. 
Outcomes Mortality, all-cause re-hospitalisation, HF-related quality of 
life, HF self-efficacy, HF knowledge, reported weight 
monitoring (self-management behaviour). 
Follow-up length  12 months 
Notes  
 
Doughty R N, 2002  
Participants 197 patients with diagnosis of heart failure 
Mean age  73 
Male percentage 60 
Country New Zealand 
Interventions  Patients randomized to the intervention group were scheduled 
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for an outpatient clinical review with the study team within 2 
weeks of hospital discharge. At this initial clinic visit the 
patient’s clinical status was reviewed, with particular attention 
to possible remediable exacerbating factors. One-on-one 
education with the study nurse was initiated at the first clinic 
visit. A patient diary, for daily weights, medication record, 
clinical notes and appointments, and education booklet were 
provided. A follow-up plan was devised for each patient 
aiming for 6-weekly visits alternating between the GP and 
heart failure clinic, although the patients were free to see their 
GPs at any time they wished. A detailed letter was faxed to the 
GP on the same day as the patient visited the heart failure 
clinic. This letter included summary comments outlining the 
rationale for any changes in treatment, and was followed-up 
with a phone call to the patient’s GP to discuss any relevant 
changes in the management plan. The aim was for a close 
liaison between the patient and family, the GP and the hospital 
heart failure clinic. GPs made changes to the patient’s 
management as they saw fit but were encouraged to discuss 
aspects of the patient’s management with the clinic team at any 
stage. Subsequently, group education sessions (each lasting 
1·5–2 h) were offered, two within 6 weeks of hospital 
discharge and a further after 6 months. These sessions were 
run by a cardiologist and the study nurse. The content of the 
one-on-one and group education included explanation of the 
symptoms and signs of heart failure, importance of monitoring 
of daily body weight and action plans should weight change, 
effects of medications and importance of compliance and 
recommendations regarding exercise and diet. The advice 
given was individualized and reinforced at each subsequent 
clinic visit by the study nurse. Monitoring of daily weights, 
with documentation in the diary and knowing what action to 
take should weight change, was reinforced at every available 
opportunity, either in the clinic or during phone calls with the 
patient. No assistance with travel costs or other incentives 
were provided for the patients in the intervention group. 
The study team at the hospital heart failure clinic was available 
for consultation during normal working hours and received 
calls from both patients and their GPs. At times of worsening 
symptoms patients were initially advised to see their GP. No 
explicit criteria for readmission were pre-specified and the 
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decision to request admission rested with the GP. If admission 
was not required then an earlier heart failure clinic visit could 
be arranged. 
Patients randomized to the control group continued under the 
care of their GP with additional follow-up measures as usually 
recommended by the medical team responsible for their in-
patient care.  
Outcomes Mortality, hospital readmission, quality of life 
Follow-up length  12 months 
Notes  
 
Dunagan W C, 2005  
Participants 151 patients hospitalized with heart failure 
Mean age  70 years 
Male percentage 37% 
Country USA 
Interventions  At enrollment, the program was described to each enrollee’s 
primary physician and permission requested to adjust diuretic 
doses as needed, which was granted in 27 instances. Primary 
physicians were contacted directly about patients in either 
group with a Beck Depression Inventory (BDI) score 
suggesting possible depression or who answered affirmatively 
to questions concerning suicidal ideation. 
Patients in both groups received an educational packet 
describing the causes of HF, the basic principles of treatment, 
their role in routine care and monitoring of their condition, and 
appropriate strategies for managing a HF exacerbation. The 
intervention group received additional education from study 
nurses during scheduled telephone contact. Twenty patients 
also received 1 or more home visits, and 18 patients were 
provided bathroom scales. 
The intervention included regularly scheduled telephonic 
monitoring by specially trained nurses supervised by 
cardiologists specializing in HF. Calls were used to promote 
self-management skills, appropriate diet, and adherence to 
guideline-based therapy prescribed by primary physicians. 
Patients were encouraged to contact program nurses any time 
they experienced an increase in symptoms or had questions 
about their disease or treatment. During telephone contacts, 
nurses screened patients for HF exacerbations and 
administered a standardized screening instrument developed to 
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detect such changes. If there was evidence of an exacerbation, 
program nurses recommended that the patient take 
supplemental diuretics or contacted the patient’s physician for 
instructions. Patients were called within 3 days after hospital 
discharge or program enrollment and then at least weekly for 2 
weeks. Call frequency subsequently was adjusted based on 
program nurses’ assessments of patients’ clinical status and 
self-management abilities. 
Outcomes Mortality, readmission 
Follow-up length  12 months 
Notes  
 
Ekman I,  1998  
Participants 192 patients with heart failure hospitalzed 
Mean age  76 years 
Male percentage 55% 
Country Canada 
Interventions  Usual care for hospital-to-home transfer involves completion 
of medical history, nursing assessment form, and, in ideal 
circumstances within 24 hours of hospital admission, a 
multidisciplinary discharge plan. Weekly discharge planning 
meetings further identify patient needs. A regional home care 
co-coordinator consults with the hospital team as required and 
may meet directly with patients and families. Immediately 
before discharge, a physician completes a referral for home 
care, and necessary services and supplies are communicated to 
the home nursing agency. Usual home nursing care for CHF 
patients includes assessment and monitoring, health teaching, 
provision of direct care, eg, administration of medications, and 
managing equipment and treatments. 
Patients in the Intervention Group (Transitional Care - TC) 
arm received the standard discharge planning and care, plus a 
comprehensive program, adding supports to improve the 
transfer from hospital to home. To develop this program, 
hospital and community nurses met to focus on the 'outreach' 
from the hospital and 'in-reach' from the community during the 
transition. An intersectoral continuity of care framework 
guided their efforts in identifying gaps to specifically address 3 
major aspect of a hospital-to-home transition: (1) supportive 
care for self-management; (2) linkages between hospital and 
home nurses and patients; and (3) the balance of care between 
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the patient and family and professional providers. The defining 
characteristics of TC were the use of a structured, 
comprehensive, evidenced-based protocol for counselling and 
education for heart failure selfmanagement, plus additional and 
planned linkages to support individuals in taking charge of 
aspects of their care. An evidence-based intervention is 
defined as care based by current research or, in the absence of 
strong empirical findings, on expert consensus. This may 
involve the use of professional practice standards and practice 
guidelines, if available. 
The education-counseling protocol entitled, Partners in Care 
for Congestive Heart Failure (PCCHF), was developed in 
response to AHCPR guideline recommendations.  PCCHF has 
two clinical components: (1) the patient workbook, and (2) an 
education map that provided the overall education plan, and 
serving as a patient-held documentation tool. The workbook, a 
comprehensive resource for self-management, provides a 
structured approach for patient education, yet allows for 
tailoring to individual needs. It covers the basics of heart 
function and self-monitoring, what CHF means, management 
of medications, diet, exercise, stress, support systems, and 
community resources. There is a pocket for inserting patient-
specific information (eg, medication, dietary handouts). 
Linkages, additional to usual practice, were created among 
providers and the patients including: a nursing transfer letter to 
the home care nurse detailing clinical status and 
selfmanagement  needs; a telephone outreach from the hospital 
nurse within 24 hours of discharge; notification to home care 
as to whom hospital primary nurse was for follow-up consult if 
necessary; and a patient-held documentation tool. 
Outcomes Readmission, quality of life 
Follow-up length  12 weeks 
Notes  
 
Galbreath A D,  2004  
Participants 1069 patients with symptoms of CHF and documented systolic 
(mean EF 35%) or diastolic dysfunction (echo confirmed). 
Mean age  71 years 
Male percentage 71 % 
Country USA 
Interventions  All intervention patients received bathroom scales and were 
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designated a disease manager who administered the disease 
management program telephonically. Initial call frequency was 
weekly then transitioned to monthly for the duration of the 
study. Call frequency could be adjusted for acuity or need. 
After each call a call summary was faxed to the patients 
primary care provider. 
An additional randomisation was performed within the 
intervention arm, with some participants provided with in-
home technology (BP monitor, pulse oximeter) – these 
measurements were reported by the patient to the disease 
manager, but the data were not forwarded to the primary care 
provider. These patients also wore activity monitors at regular 
intervals and had six-monthly measurement of thoracic 
bioimpedance cardiac output - these data were not forwarded 
to the primary care physician. The authors state: ―because data 
derived from the technology were not used in clinical 
management, we combined results from the two treatment 
groups for the purposes of this analysis.‖ 
Traditional care patients were managed as usual by their 
physicians. 
Outcomes All-cause mortality, six-min walk performance, functional 
therapeutic class improvement, 
total healthcare costs. Improvement in ejection fraction 
improvement and medication adherence were assessed in a 
subgroup. 
Follow-up length  18 months 
Notes  
 
Gattis W A,  1999  
Participants Participants 181 patients with heart failure being evaluated in 
cardiology clinic. 
 
Mean age  67 years 
Male percentage 68% 
Country USA 
Interventions  Clinical pharmacist-led medication review and patient 
education. Regularly scheduled telephone contact (at two, 12 
and 24 weeks) to detect clinical deterioration early. 
The control group received usual care which did not include 
the pharmacist providing recommendations regarding drug 
therapy to the attending physician or providing education to 
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the patient. Patient assessment and education were provided by 
the attending physician and/or physician assistant or nurse 
practitioner. The patient was contacted by the pharmacist via 
telephone to identify clinical events. 
Outcomes Mortality, rehospitalisation, medication prescription. 
Follow-up length  6 months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
 
Hughes S L, 2000  
Participants 30 patients with Heart Failure 
Mean age  No available descriptive data for HF patients 
Male percentage No available descriptive data for HF patients 
Country USA 
Interventions  The treatment incorporated key features of integrated 
networks, including systematic screening to identify high risk 
patients, an emphasis on continuity of care, and the 
management of patients across organizational boundaries. 
Participating sites were asked to provide continuous patient 
care management with the home-based care physician serving 
as the primary care physician. Patients continued to receive 
homecare for as long as needed, until maximum patient benefit 
was achieved, or until a different level of care was required. 
Sites used clinical judgment to provide visits based on patient 
condition and need.  
Outcomes Patient functional status, patient and caregiver HRQoL 
and satisfaction, caregiver burden, hospital readmissions, and 
costs 
Follow-up length  12 months 
Notes  
 
Jaarsma T, 1999  
Participants 179 patients hospitalized with heart failure 
Mean age  73 years 
Male percentage 58% 
Country Netherlands 
Interventions  The supportive–educative intervention consisted of intensive, 
systematic and planned education by a study nurse about the 
consequences of heart failure in daily life, using a standard 
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nursing care plan developed by the researchers for heart failure 
patients in older age. Important topics were discussed with 
every patient, for example, recognition of warning symptoms 
of worsening heart failure, sodium restriction, fluid balance, 
and compliance. In addition, individual problems were 
discussed, for example problems in social interaction, sexual 
function or limited access to the general practitioner. 
During hospital stay, the study nurse assessed the patients’ 
needs, provided education and support to the patient (and 
family), gave the patient a card with warning symptoms and 
discussed discharge. Within 1 week after discharge the study 
nurse telephoned the patient to assess potential problems and 
to make an appointment for a home visit. During the home 
visit the study nurse reinforced and continued education as 
warranted by the patient situation. If needed, the information 
was given to a carer about specific patient needs. 
Between discharge and the home visit, patients could call the 
study nurse in case of problems. After the home visit, the 
patient was advised to call their cardiologist, general 
practitioner or emergency heart centre in case of difficulties. 
The intervention lasted from hospital admission to 10 days 
after discharge from hospital. 
Patients assigned to the care as usual (control group) received 
all standard care. This meant that they were not provided with 
structured patient education, a follow-up telephone call or a 
home visit by a nurse. Dependent on the insight of an 
individual nurse or physician the patient received information 
(in writing or oral) about medication and lifestyle. Patients 
from the control and intervention groups were never assigned 
to the same room on the nursing unit. The two study nurses 
were involved in data collection as researcher and research 
assistant. However, the person who collected the data and the 
nurse who visited the patient for the intervention were never 
the same. 
Outcomes Mortality, readmission, hospital staying  
Follow-up length  9 months 
Notes  
 
Kasper E K, 2002  
Participants 200 patients hospitalized with Chronic Heart Failure 
Mean age  64 years (median) 
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Male percentage 60% 
Country USA 
Interventions  Intervention group. The four members of the intervention team 
were the telephone nurse coordinator, the CHF nurse, the CHF 
cardiologist and the patient’s primary physician. The telephone 
nurse coordinator made follow-up calls to patients from a 
central site located in Rockville, Maryland. Telephone calls 
were placed within 72 h of hospital discharge, then weekly for 
one month—twice in the second month and monthly 
thereafter, unless a problem occurred that required more 
frequent contact. The telephone nurse coordinator followed a 
set script and pursued problems as clinically indicated, but did 
not adjust medications over the telephone. The CHF nurses 
were assigned to assist the intervention group and helped to 
implement the therapeutic plan designed by the CHF 
cardiologists. Patients had at least monthly follow-up with 
these nurses. Most visits occurred in CHF clinics located at 
each site, but some occurred in the patient’s home. The CHF 
nurses adjusted medications under the directions of the CHF 
cardiologists, following a prespecified algorithm, which 
included initiation and titration of angiotensin-converting 
enzyme (ACE) inhibitors, beta-blockers and diuretics. The 
algorithm included a 2-g sodium-restricted diet, as well as a 
recommendation to exercise by walking for 20 min at least 
four days per week. The treatment plan was individualized for 
each patient. In the course of the study, the algorithm was 
updated to include, for example, the use of beta-blockers. All 
members of the team, except for the patients’ primary 
physicians, participated in weekly patient care meetings. 
The CHF cardiologists designed and documented a treatment 
plan for all study patients before randomization and saw the 
patients at baseline and six months. They designed the 
prespecified algorithm according to available CHF guidelines 
and clinical experience. The primary physicians approved of 
their patients’ participation, as well as medication, dietary, 
activity and follow-up regimens. They managed all problems 
not related to CHF, received regular updates from the CHF 
nurses and were notified of abnormal laboratory values. 
Patients in the intervention group with limited financial 
resources were provided, if needed, a scale, a 3-g sodium 
―Meals on Wheels‖ diet, medications, transportation to the 
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clinic and a telephone. All patients in the intervention group 
were supplied with a pill sorter, a list of correct medications, a 
list of dietary and physical activity recommendations, a contact 
number available 24 h/day and patient education material.  
Patients assigned to the non-intervention group were cared for 
by their primary physicians. The baseline therapeutic plan 
designed by the CHF cardiologist was documented in the 
patient’s chart, without further intervention.  
Outcomes death, CHF hospital admissions, total hospital admissions, 
changes in quality of life  and activity status. 
Follow-up length  Six months 
Notes  
 
Krumholz H M, 2002  
Participants 88 patients hospitalized with heart failure 
Mean age  74 years 
Male percentage 57% 
Country USA 
Interventions  The study intervention was based on five sequential care 
domains for chronic illness, including patient knowledge of the 
illness, the relation between medications and illness, the 
relation between health behaviours and illness, knowledge of 
early signs and symptoms of decompensation and where and 
when to obtain assistance. In the teaching module, each 
sequential domain supplemented knowledge acquired in 
previous domains. Operationalizing the intervention occurred 
in two phases. Initially, the patients’ understanding of the 
domains was assessed and reviewed in order to provide 
information about patient gaps in knowledge for the nurse to 
address. Subsequent follow-up sessions reviewed knowledge 
of care domains and provided support for patients to apply 
their knowledge, participate in managing these domains and 
effectively seek and access care. This support was designed to 
reinforce the initial educational foundation theoretically by 
empowering patients and offering strategies to improve 
patients’ compliance. 
For the initial phase, an experienced cardiac nurse educated 
patients during an hour-long face-to-face in-depth session 
within two weeks of hospital discharge using a teaching 
booklet. Home visits were performed for 45% of intervention 
patients unable to travel to the hospital, but the visits were not 
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intended to provide additional assessments that were more 
detailed than clinic sessions. Neither clinical assessment of HF 
nor modification of current medical regimen was a component 
of the baseline meeting. During the subsequent telemonitoring 
phase, the nurse contacted the patient by phone on a weekly 
basis for four weeks, then biweekly for eight weeks and then 
monthly for a total intervention period of one year. These calls 
reinforced care domains but did not modify current regimens 
or provide recommendations about treatment. However, the 
nurse could recommend that the patient consult his or her 
physician when the patient’s status deteriorated abruptly or the 
patient experienced a significant problem with medical therapy 
requiring prompt attention, and, in doing so, the nurse helped 
patients understand when and how to seek and access care. 
Patients assigned to the control group received all usual care 
treatments and services ordered by their physicians. 
Outcomes Mortality, readmission, days of hospitalization 
Follow-up length  12 months 
Notes  
 
Mejhert M,  2004  
Participants 208 patients with heart failure 
Mean age  75 years 
Male percentage 58% 
Country Sweden 
Interventions  A senior cardiologist supervises the intervention programme. 
After referral to the programme, the patient pays regular visits 
to the outpatient clinic and is encouraged to keep in contact 
with the nurse. At each visit the nurse checks symptoms and 
signs of heart failure, blood pressure, heart rate, and weight. 
Laboratory tests measure creatinine, sodium, and potassium 
concentrations. Nurses working in the programme are allowed 
to institute and change the doses of angiotensin converting 
enzyme (ACE) inhibitors, angiotensin II receptor blockers, 
beta enoceptor blockers, potassium substitution, diuretics, and 
potassium sparing diuretics according to a standard protocol. 
The patient is instructed to check his or her weight regularly 
and to monitor early signs of deterioration. Patients with good 
compliance are instructed to change dosing of diuretics on 
their own. Dietary advice recommends restricted sodium, fluid, 
and alcohol intake. Information is repeated in booklets and 
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computerised educational programmes. According to the 
routine, written information is given in a structured format to 
the general practitioner at discharge of a patient from our 
institution.  
Patients randomised to the control group typically were 
followed up by their general practitioners to be treated 
according to the local health care plan for heart failure. If left 
ventricular systolic function is reduced, with an ejection 
fraction , 40%, an ACE inhibitor should be initiated. Several 
meetings with hospital specialists and general practitioners 
have addressed the importance of optimised medication and 
education of patients with heart failure. In addition to the visits 
outlined above, all patients were scheduled for clinical 
examinations and detailed control of medication at 6, 12, and 
18 months. One and the same cardiologist met the patients at 
all visits. The patients were informed at the start of the study 
that these visits were purely observational and with no 
intention to initiate examinations or to change medication. 
Outcomes Hospitalization, mortality, quality of life 
Follow-up length  18 months 
Notes  
 
Naylor M D, 2004  
Participants 142 
Mean age  76 years 
Male percentage 49% 
Country USA 
Interventions  Patients in the control group received the hospital's routine 
discharge plan, which is used for patients of all ages and 
diagnostic classifications. Criteria-based screening of all 
hospital admissions normally occurred within 48 hours of 
admission. Uncomplicated discharges were managed by the 
patient's physician and primary nurse. Complicated discharges, 
which necessitated coordination of services and external 
providers, involved social workers and community nursing 
coordinators employed by the hospital. Discharge planning 
services were provided in accordance with the medical plan of 
care. 
Patients and caregivers in the intervention group received the 
hospital's routine plan and a comprehensive, individualized 
discharge planning protocol developed specifically for elderly 
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patients and implemented by gerontologic clinical nurse 
specialists. The protocol extended from hospital admission to 2 
weeks after discharge. Compared with the hospital's routine 
procedure, the discharge planning protocol included the 
following unique features: 1) comprehensive initial and 
ongoing assessment of the discharge planning needs of the 
elderly patient and his or her caregiver; 2) development of a 
discharge plan in collaboration with the patient, caregiver, 
physician, primary nurse, and other members of the health care 
team; 3) validation of patient and caregiver education; 4) 
coordination of the discharge plan throughout the patient's 
hospitalization and through 2 weeks after discharge; 5) 
interdisciplinary communication regarding discharge status; 
and 6) ongoing evaluation of the effectiveness of the discharge 
plan. 
Two half-time nurse specialists with master's degrees in 
gerontologic nursing and a minimum of 1 year of practice as a 
nurse specialist were hired to implement the comprehensive 
discharge planning protocol for patients in the intervention 
group. Within 24 to 48 hours of admission, the nurse specialist 
visited the patient and contacted the caregiver to complete the 
initial patient and caregiver assessment and to document the 
preliminary discharge plan. 
The nurse specialist visited the patient every 48 hours 
thereafter to implement the plan through patient and caregiver 
education, referrals, consultation with health care team 
members, counseling, and coordination of home services. The 
final visit was made within 24 hours of discharge to finalize 
discharge preparations. Summaries of the discharge plan were 
recorded in the patient's chart and distributed to the patient, 
primary care physician, and other health care team members 
who would care for the patient at home. 
In addition to personal visits, the nurse specialist was available 
7 days a week by telephone (8 a.m. to 10 p.m. on weekdays; 8 
a.m. to l2p.m. on weekends) throughout the patient's 
hospitalization and for 2 weeks after discharge for any 
questions or concerns from the patient, caregiver, or health 
care team member that were relevant to the discharge plan. 
The nurse specialist also initiated a minimum of two telephone 
calls during the first 2 weeks after discharge to monitor the 
patient's progress and intervene when necessary. 
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Outcomes length of initial hospital stay, length of time between initial 
hospital discharge and readmission, and rehospitalization rates 
Follow-up length  12 weeks 
Notes  
 
Peters-Klimm F, 2010  
Participants 197 patients with ascertained left ventricular systolic 
dysfunction 
Mean age  70 years 
Male percentage 73% 
Country Germany 
Interventions  Patients randomised to the intervention received complex, 
structured case management by a trained doctor's assistant 
(DA): The design of the intervention addressed the 4 of the 6 
elements of the CCM (delivery system design, self-
management support, decision support, clinical information 
systems): DAs completed 6 hours of theoretical and practical 
training before conducting regular patient monitoring for 1 
year by telephone (patients with NYHA functional status III or 
IV three-weekly versus I or II six-weekly) and by 3 home 
visits for all patients. DAs gave feedback of the results of the 
monitoring and screening to their employing GP. The 
programme included the use of a CPG, a patient leaflet 
according to the national CPG, booklets and tailored diaries.. 
Additionally, GPs received graphically depicted individual 
performance feedback on evidence-based pharmacotherapy 
(from data of baseline documentation). 
For patients in the control (usual care) group, no case 
management was applied. 
Outcomes Quality of life and hospital admission 
Follow-up length  12 months 
Notes  
 
Philbin E F, 2000  
Participants 1504 patients admitted with heart failure 
Mean age  76 years 
Male percentage 44% 
Country USA 
Interventions  Physicians and nurse leaders and administrators responsible 
for quality management at the intervention hospitals 
participated in the leadership of this study and served as 
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champions for the project at their institutions. The quality 
improvement intervention attempted to maximize the 
implementation of an inpatient critical pathway for heart 
failure management, which was designed by the study 
leadership. Its format was a Gantt chart or timetask matrix. 
The pathway recommended diagnostic tests and treatments 
that were considered to be highly indicated based on published 
clinical trial results, expert guidelines, or wide acceptance as 
current standards, but omitted those considered experimental 
or controversial. Standardized admission orders, which 
supplemented the pathway, were also made available. In 
addition, we provided several other components aimed at 
improving provider and patient knowledge, expediting 
diagnosis and treatment, and reducing readmission. These 
included a critical pathway for use in the emergency 
department, which emphasized rapid diagnosis of heart failure 
and initiation of intravenous diuretic therapy, and a home care 
pathway for use by home health personnel after hospital 
discharge. An experienced consulting firm (The Center for 
Case Management, Natick, Massachusetts) assisted in 
implementation of the pathways and other components of the 
intervention. Three medical grand rounds were given at each 
hospital by regional or national experts in heart failure, and 
five lectures about clinical issues in heart failure were 
provided for nurses and other health professionals at each 
hospital. Videotapes of all eight lectures were available to 
assist in dissemination of the didactic message. Teaching aids 
were given to patients and their families. Finally, 
comprehensive hospital-specific performance and 
benchmarking reports about process and outcomes of care 
from the baseline period were presented to the intervention 
hospitals orally and as a written 45-page report as catalysts for 
changes in clinical practice. 
Outcomes Mortality, hospitalization and quality of life 
Follow-up length  6  months 
Notes  
 
Rainville E C 1999  
Participants 38 patients aged ≥ 50 years discharged from hospital with 
heart failure. 
Mean age  70 years 
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Male percentage 50% 
Country USA 
Interventions  Usual care plus a pharmacist-led medication review, patient 
education, medication management prior to discharge and at 
Day 3, Day 7, 30 days, 90 days and 12 months via telephone. 
Usual care consisted of routine care and preparation for 
discharge including written prescriptions, physician discharge 
instructions and a nurse review of diet, treatment plans and 
medications. The nurses provided the patient with computer 
generated drug information sheets. Patients were contacted by 
a pharmacist at 30 days, 90 days and 12 months to determine 
readmissions. 
Outcomes Mortality, rehospitalisation, functional assessment score. 
Follow-up length  12 months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
Rich M W, 1993  
Participants 98 patients admitted with congestive heart failure 
Mean age  79 years 
Male percentage 41% 
Country USA 
Interventions  Nurse-directed multi-disciplinary intervention including 
comprehensive education of the patient and family, a 
prescribed diet, social service consultation planning for early 
discharge, a review of medications by a geriatric cardiologist, 
and intensive follow-up through the hospital’s home care 
services, supplemented by individualised home visits and 
telephone contact. 
Outcomes Readmission 
Follow-up length  3 months 
Notes  
 
Riegel B, 2002  
Participants 358 patients discharged from hospital with heart failure. 
Mean age  74 years 
Male percentage 49% 
Country USA 
Interventions  Telephonic case management by a registered nurse using 
decision support software, involving patient education and 
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counselling and liaison with primary care physician. Patients 
were telephoned within 5 days of discharge and thereafter at a 
frequency guided by the software and case manager (mean 17 
calls). 
Usual care was not standardised, and no formal telephonic 
case-management was in existence at these institutions. These 
patients presumably received some education regarding HF 
management prior to hospital discharge. 
Outcomes Mortality, rehospitalisation, physician and emergency 
department visits, inpatient costs, patient satisfaction. 
Follow-up length  Six months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
Riegel B, 2006  
Participants 135 hospitalized Hispanic patient with CHF 
Mean age  72 years 
Male percentage 46% 
Country USA 
Interventions  Education, monitoring and guidance by bilingual-bicultural 
Mexican-American registered nurses via telephone case 
management standardised using decision support software. 
Patients were contacted on average within 5 days of discharge 
and thereafter at a frequency guided by the software and nurse 
case manager over a 6 month period (mean 13.5 calls to 
patients and 8.4 additional calls to families). Printed 
educational material was provided monthly and upon request 
in the relevant language. 
Usual care was not standardised and no formal disease 
management program existed at these institutions. The 
standard of usual care was that patients were educated 
regarding HF management before discharge, assuming that the 
nurse spoke the patient’s language or someone bilingual was 
available to translate. In reality, only a small portion of staff 
were bilingual. 
Outcomes Mortality, re-hospitalisation, cost of care, self-reported health-
related quality of life and depression. 
Follow-up length  Six months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
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Participants Participants 406 non-Hispanic and Hispanic patients with 
documented systolic dysfunction. 
Mean age  59 years 
Male percentage 54% 
Country USA 
Interventions  An in-person appointment was arranged for each intervention 
patient, which included symptom and disease education and 
referral to additional patient services (if required). 
Follow-up telephone calls consisted of patient assessment, 
recording of admission information reinforcement of self-
monitoring and administration of a food-frequency 
questionnaire (at 2, 4, 8, 12 and 24 weeks and a report sent to 
patients). Intervention nurses coordinated flow of information 
between patient and clinician and arranged medication 
adjustment and required examinations. 
Usual care patients received guidelines for managing systolic 
dysfunction, but no other care information was specified. 
Outcomes Mortality, hospitalisations, functional status (including quality 
of life). 
Follow-up length  12 months 
Notes  
 
Stewart S 2002  
Participants 297 patients with congestive heart failure 
Mean age  75 
Male percentage 84% 
Country Australia 
Interventions  Patients assigned to intervention group, while receiving the 
same level of care as those assigned to ―usual care,‖ received a 
structured home visit within 7 to 14 days of discharge. The 
fundamental aim of intervention is to optimize the 
management of the patient’s chronic disease state(s) and to 
facilitate the rapid recognition and treatment of potential 
problems. Initial assessment included a physical examination 
and a review of the patient’s adherence to, and knowledge of, 
prescribed treatment and their social support system, in 
addition to identification of any other factors likely to increase 
the probability of readmission or death. A report (with 
recommendations) was sent to the patient’s treating physicians 
and a combination of short- and long-term strategies applied. 
The nurse played a pivotal role in both studies by coordinating 
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efforts to optimize the patient’s management and providing a 
critical link to the appropriate health care if problems arose. 
Outcomes Mortality, hospitalization, healthcare cost 
Follow-up length  4.2 years (median) 
Notes  
 
Stromberg A, 2003  
Participants 106 Patients hospitalized with heart failure 
Mean age  78 years 
Male percentage 52% 
Country Sweden 
Interventions  The patients in the intervention group were followed up at a 
nurse-led heart failure clinic staffed by specially educated and 
experienced cardiac nurses, delegated the responsibility for 
making protocol-led changes in medications. The first visit 
was scheduled 2–3 weeks after discharge. All visits lasted for 
1 h and the nurse evaluated the status and if the heart failure 
treatment was optimised, gave education about heart failure 
and social support to the patient and his family. The status 
taken during the visit included anamnesis, auscultation of heart 
and lungs and inspection of oedema. If treatment needed to be 
optimised, the cardiologist with medical responsibility for the 
heart failure clinic was consulted and treatment changed in 
accordance with current clinical guidelines. For example the 
dose of the ACE-inhibitor and/or beta-blocker could be 
increased if reaching the target-dose or highest tolerable dose 
was not done during hospitalisation. The education was 
individualised, included both written and verbal information 
and was based on guidelines. The patients and their families 
were educated on heart failure and the content included 
definition and symptoms/signs of heart failure, aetiology, 
rationale for treatment and drug counselling. It also included 
non-pharmacological treatment with dietary changes such as 
restricted fluid, sodium and alcohol intake, individually 
adjusted energy intake in order to reduce overweight or 
prevent malnutrition, smoking cessation, exercise in stable 
heart failure and infection prophylaxis with vaccinations. The 
nurses adjusted the education to previous knowledge, 
educational level and cognitive function of the patient. The 
education specially aimed at assisting patients to improve their 
self-care regimen e.g. maintain a flexible regimen with loop-
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diuretics, restrict the intake of fluids and sodium and monitor 
symptoms such as weight gain, increased breathlessness and 
oedema daily. Another important component of the nursing 
intervention was to provide psychosocial support by creating a 
supporting relationship between the nurse and the patient. The 
patients could contact the nurses at the heart failure clinics 
during daily telephone hours (8 a.m.–5 p.m. during weekdays) 
and the heart failure nurses called patients in order to provide 
psychosocial support, evaluate drug changes or other actions 
taken due to deterioration and side effects. If the patient was 
unstable with symptoms of worsening heart failure at the time 
of the follow-up visit or if further education was needed, the 
patient was scheduled for another visit to the heart failure 
clinic. When the patients were stable and well informed, they 
were referred back to their general practitioner in primary 
health care.  
All patients in the control group were managed in accordance 
with current clinical practice and received conventional 
follow-up in primary health care. The responsible physicians 
in the primary health care were free to evaluate and treat the 
patient according to their own judgement. Some patients got a 
scheduled visit after discharge, but most patients were 
encouraged to phone primary health care if they had problems 
due to heart failure. There were no specialised heart failure 
nurses, no standardised education or structured follow-up for 
patients with heart failure at any of primary health care 
centres. 
Outcomes Mortality, number of readmissions for any reason, number of 
days in hospital and self-care behaviour. 
Follow-up length  12 months 
Notes  
 
Thompson DR, 2005  
Participants 106 patients admitted with Chronic Heart Failure 
Mean age  73 years 
Male percentage 73% 
Country UK 
Interventions  The patients allocated to the UC group received standard care 
(i.e. explanation of their condition and prescribed medications 
by the ward nurse and referral to appropriate post-discharge 
support as required). Patients were given an outpatient 
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department appointment 6–8 weeks post discharge according 
to individual consultant practice. The study intervention was 
primarily applied by two nurses experienced in the 
management of heart failure and with postgraduate 
qualifications, using strict treatment protocols. As such, 
patients allocated to intervention group were seen by the study 
specialist nurses prior to their discharge and received a home 
visit within 10 days of hospital discharge. At the ward visit, 
patients received information on their condition, medications 
and what to expect when they went home. An appointment 
was arranged at a time of the patient’s convenience for the 
home visit. In addition, the patient was given a card with a 
contact telephone number for the specialist nurse (office hours 
only) where messages could be left regarding any questions or 
queries the patient or their family may have. At the home visit, 
patients (and their family if appropriate) received education on 
their condition, including symptom recognition, symptom 
management and lifestyle issues. A thorough clinical 
examination, involving a review of their clinical history since 
hospital discharge, functional status, vital observations, heart 
and lung sounds and hydration status was also performed. All 
patients accepted an invitation to attend a monthly nurse-led 
outpatient heart failure clinic for at least 6 months post 
discharge. However, concomitant illness (e.g. influenza), early 
post discharge death and the logistics of travelling to the clinic 
meant that only 79% of the patients attended all their clinic 
sessions. During the clinic visits patients (and their family if 
appropriate) received a full educational package, including 
diagnosis, symptom recognition, symptom management, 
lifestyle issues and crisis management. A clinical examination 
(see above) was performed to assess cardiac status and fluid 
retention. Weight, electrolytes, renal, hepatic function and 
blood counts were monitored. New therapeutic agents (e.g. 
Spironlactone) were also commenced according to local 
protocol based upon the Taskforce Recommendations of the 
European Society of Cardiology (2000) and the Scottish Inter 
Collegiate Guidelines (1999). Where appropriate, referral to 
other local health and social services was made. 
Outcomes Hospital stay, mortality, quality of life 
Follow-up length  6 months 
Notes  
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Tsuyuki R T, 2004  
Participants 276 patients discharged from hospital with heart failure. 
Mean age  72 years 
Male percentage 58% 
Country Canada. 
Interventions  Early discharge planning with provision of adherence aids, 
patient education, regularly scheduled telephone contact with 
local research coordinator at two and four weeks then monthly 
thereafter for six months. Recommendations to see primary 
care physician if not on target dose ACE inhibitor or 
deterioration. 
Patients assigned to usual care received a general heart disease 
pamphlet before discharge, but no formal counselling beyond 
what was routine at the hospital. Patients were contacted 
monthly for six months to ascertain clinical events. 
Outcomes Mortality, re-hospitalisation, medication adherence, physician 
and emergency department visits, cost-analysis. 
Follow-up length  Six months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
Wakefield B J,2008  
Participants 148 patients hospitalised for HF exacerbation. 
Mean age  69 years 
Male percentage 99% 
Country USA 
Interventions  Patients allocated to the intervention group were allocated to 1 
of 2 interventions: telephone follow-up or videophone follow-
up. Intervention patients were contacted by a nurse 3 times in 
the first week then weekly for 11 weeks. Symptoms and the 
patients discharge plan was reviewed and reinforced as well as 
referrals made if required. Additionally, the intervention 
nurses employed behaviour skill training strategies tomaximise 
self-management, self-monitoring and self-efficacy. 
Usual care was not specified except to state that ―subjects 
contacted their primary care nurse case manager by telephone 
if needed‖. 
Outcomes Mortality, readmissions, hospital days, time to first 
readmission, urgent care clinic visits, quality of life, 
intervention dose and technical issues. 
Follow-up length  12 months  
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Notes Telephone and video-telephone intervention arms were 
combined and classed as disease management program 
 
Weinberger M,  1996  
Participants 504 patients  
Mean age  98% 
Male percentage 63 
Country USA 
Interventions  The intervention was delivered by a team consisting of one 
licensed registered nurse and one primary care physician.  
The intervention had both an inpatient component, which 
began immediately after randomization, and an outpatient 
component, which began at discharge. 
Control Group 
The care of patients in control group after discharge could be 
provided by community physicians or at Veterans Affairs 
clinics, as arranged by the physicians treating them as 
inpatients. The control patients did not have access to the 
primary care nurse and received no supplemental education or 
assessment of needs beyond what was customarily offered at 
each site. 
Outcomes Readmission, length of hospital stay, quality of life 
Follow-up length  6 months 
Notes  
 
Young W, 2003  
Participants 715 consecutive patients admitted with elevated cardiac 
markers 
Mean age  69 years 
Male percentage 70 
Country Canada 
Interventions  The DMP included 6 home visits by a cardiac-trained nurse, a 
standardized nurses’ checklist, referral criteria for specialty 
care, communication with the family physician and patient 
education. 
Outcomes Readmission days 
Follow-up length  1000 days 
Notes  
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2.2 Telemedicine services: home-monitoring 
Home-monitoring (HM) services are models in which the disease 
management is integrated with remote monitoring of signs, symptoms, 
physiological parameters or biomedical signals. This implies that HM is 
generally a more complex model than DMP, requiring the use of more 
complex technologies. In literature there are many different models of 
Home Monitoring (HM)[12].  
From a literature research (for details about the keywords adopted see 
section 2.3), 11 randomized clinical trials (RCTs) comparing HM and usual 
care in patients suffering from CHF were identified. The most important 
information of these studies were reported in the Table 2 
 
Table 2: characteristics of the studies comparing Home-Monitoring with Usual 
Care 
Antonicelli R,  2008  
Participants 57 patients hospitalised for worsening symptoms and signs of 
CHF with NYHA class II-IV, evidence of pulmonary 
congestions on chest x-ray and EF < 40%. Patients with 
NYHA class II-III with an EF > 40% and diastolic LV 
dysfunction were also included. 
Mean age  78 years. 
Male percentage 61% 
Country Italy 
Interventions  Patients randomised to home telemonitoring-based care were 
contacted by telephone at least once a week to collect 
information on symptoms and treatment adherence as well as 
BP, HR, weight and 24h urine output on the previous day. A 
weekly ECG transmission was also obtained. Patients were 
then evaluated and their regimen altered when necessary based 
on this data. Additionally, clinic visits were performed when 
required based on the data collected or telephone interviews. 
Usual care involved receiving standard care based on routinely 
scheduled clinic visits (every four months) performed by a 
team specialized in CHF patient management. These subjects 
were also contacted monthly by telephone to collect data on 
new hospital admissions, complications and death. Additional 
clinic visits were performed whenever required when clinical 
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status altered 
Outcomes Combined rate of mortality and hospitalisation, these rates 
considered individually, quality of life 
Follow-up length  12 month 
Notes  
 
Balk A H,  2008  
Participants 214 patients with CHF NYHA class I-IV 
Mean age  66 years 
Male percentage 70% 
Country The Netherlands 
Interventions  Patients in the Intervention group were provided a MOTIVA 
system (TV-channel providing educational material, reminders 
of medication, health related surveys and motivational 
messages to encourage the prescribed lifestyle regimen) in 
addition to scheduled cardiologist appointments.  
A subgroup of intervention patients also received automated 
BP and weight devices that automatically communicated 
readings via the telephone (those who had been hospitalised in 
the prior year for HF). Patient guidance followed a 
personalised plan.  
Control subjects were followed by their cardiologists and HF-
nurses according to standard local practice. 
All patients recorded all contacts with healthcare professionals 
and hospital admissions. 
Outcomes All-cause hospital days per year, days alive and out of hospital, 
quality of life, knowledge of disease, self-care. 
Follow-up length  288 days (mean value) 
Notes  
 
Bourge R C, 2008  
Participants 274 patients with CHF NYHA class III or IV, who received an 
implantable continuous hemodynamic monitor 
Mean age  58 years 
Male percentage 65% 
Country USA 
Interventions  All patients received the ICHM system (Model 9520, 
Medtronic) and optimal medical therapy.  
The ICHM system consists of: 1) a programmable device that 
processes and stores information and is similar in appearance 
to the pulse generator of a pacemaker; and 2) a transvenous 
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lead (model 4328A, Medtronic) that has a sensor incorporated 
near its tip to measure intracardiac pressure. The implantation 
procedure is similar to that of a single-lead pacemaker system, 
with the device positioned subcutaneously in the pectoral area 
and the lead positioned transvenously in the right ventricular 
outflow tract or septum. It is capable of continuously 
monitoring and storing heart rate, body temperature, patient 
activity, right ventricular systolic and diastolic pressure, 
maximal positive and negative rate of change in right 
ventricular pressure (dP/dt), right ventricular pre-ejection and 
systolic time intervals, and estimated pulmonary arterial 
diastolic pressure (ePAD). 
The hemodynamic information from the monitor was used to 
guide patient management only in the treatment group 
Outcomes HF-related hospitalization, emergency department access,  
Follow-up length  6 months 
Notes  
 
de Lusignan S 2001  
Participants 20 patients with heart failure confirmed by cardiologist, 
identified from the database of an academic general practice. 
Mean age  75 years 
Male percentage not specified 
Country UK 
Interventions  Telemonitoring of vital signs (pulse, BP, weight) and clinical 
status daily assessed daily by nurses along with video consults 
with a nurse weekly for three months, fortnightly for three 
months, then monthly. 
Usual care consisted of standard general practice treatment; in 
addition they had their pulse, BP and weight measured 
quarterly. They were evaluated in the same manner as the 
intervention group 
Outcomes Mortality, compliance with intervention and medication, 
patient satisfaction, quality of life 
Follow-up length  12 months 
Notes Included in previous systematic review and meta-analysis 
Clark 2007a. 
 
Giordano A,  2009  
Participants 460 confirmed CHF patients with LVEF < 40% and at least 
one hospitalisation for acute HF in the prior year. 
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Mean age  57 years 
Male percentage 85% 
Country Italy 
Interventions  Home-Based Telemanagement (HBT) patients received a one-
lead trace portable device that transferred results via telephone 
where a nurse was available for interactive teleconsultation. 
Scheduled standardised telemonitoring appointments were 
performed every week to 15 days depending on HF severity 
discussing symtomology, medications, self-care and, if 
required, the transmission of the ECG trace.  
Usual care consisted of patients being referred to their primary 
care physician (PCP) and cardiologist for clinical management. 
These patients attended a two-weeks post-discharge PCP 
appointment and a structured follow-up outpatient cardiologist 
appointment at 12 months. 
Outcomes Unplanned cardiovascular hospital readmissions, 
hospitalisation for HF, haemodynamic instability episode 
occurrence, cardiovascular mortality. 
Follow-up length  12 months 
Notes  
 
Goldberg L R, 2003  
Participants 280 patients hospitalised with NYHA Class III-IV, with a 
LVEF < 35%. 
Mean age  59 years 
Male percentage 68% 
Country USA 
Interventions  Daily transmission of weight and symptoms using a 
customised monitor, data was reviewed daily by nurses and 
concerns reported to the physician. 
Patients in the control group were instructed to contact their 
physician for weight increases of more than a pre-specified 
amount or if their symptoms of heart failure worsened. 
They had a weight log to bring to visits. Follow-up visits, other 
than study visits were at the discretion of the treating 
physician. Telephone contacts were permitted at the discretion 
of the treating physician or nurse. 
Outcomes Mortality, rehospitalisation, emergency department visits, 
quality of life, patient satisfaction, compliance with 
intervention. 
Follow-up length  Six months 
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Notes  
 
Kashem A, 2008  
Participants 48 patients with CHF NYHA class II-IV 
Mean age  53 years 
Male percentage 74% 
Country USA 
Interventions  For all patients care is guideline-based with tailored 
medication therapy based on the patient’s clinical status, 
comorbidities, drug tolerance, age, and ethnic background. 
All patients were given a digital sphygmomanometer, a 
pedometer, and a scale when needed. They were instructed on 
their use and encouraged to self-monitor at home. These 
devices were typical off-the-shelf device available in most 
pharmacies. The patients recorded their blood pressure, body 
weight, and total number of steps/day in a logbook and 
manually entered their blood pressure, weight using calibrated 
scale, and steps data information through the secure Web site. 
All patients received the present standard care provided by 
advanced HF and cardiomyopathy program.. 
Each patient in the treatment group was instructed on how to 
use the telemedicine system. The patient was then instructed to 
send data from home within 2 days. Because the telemedicine 
system was designed for maintenance care and not for 
emergency care, patients using the system were instructed to 
either call the practice on-call number or report to the nearest 
hospital if they needed urgent or emergency care. 
Blood pressure, pulse, steps/day, and weight together with 
symptoms were entered. The most recent laboratory data and 
medication were entered by the practice staff, and the patient 
was instructed to review medications and laboratory values 
and transmit any questions to the practice. 
An advanced HF nurse was hired for this clinical study who 
was dedicated to reviewing HF patient information. She was 
responsible for communicating with the patients through the 
Web site. The study nurse talked to the patients in the Internet 
and usual care groups by telephone when status was in doubt 
or when instructions were complicated enough that verification 
of understanding was needed. The information sent to the 
patient was intended to adjust the patient’s general health 
status to maintain a stable HF state. The clinical team was 
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experienced in providing instructions to the patient by 
telephone, and the same care protocols and clinical experience 
were used for managing patients using information transmitted 
via the Internet. 
Outcomes hospital admissions, emergency department visits 
Follow-up length  12 months 
Notes  
 
Mortara A, 2009  
Participants 461 heart failure patients with NYHA class II-IV and LVEF ≤ 
40%. 
Mean age  60 years 
Male percentage 85% 
Countries UK, Poland, Italy 
Interventions  Patients allocated to home telemonitoring were further 
randomised into 3 groups. 
The first group (strategy 1) received monthly supportive 
telephone contacts from a study nurse to check on their clinical 
status. 
The second group (strategy 2) received the same telephone 
support, but also transmitted their vital signs and other data 
including details of changes in weight, BP and symptoms 
weekly by telephone. These patients also performed monthly 
24h cardiorespiratory recordings which were not made 
available to the clinical team. 
The third group (strategy 3) carried out the same 
measurements as strategy 2 patients, but the monthly 24h 
cardiorespiratory recordings were made available for clinical 
management. 
Usual care was only described as usual outpatient care. 
Outcomes Mortality and hospitalisation due to HF, all-cause mortality, 
all-cause hospitalisation, bed-days occupancy (due to 
cardiovascular cause). 
Follow-up length  11.6 months 
Notes  
 
Soran O Z, 2008  
Participants 315 patients with HF diagnosis secondary to systolic 
dysfunction (LVEF ≤ 40%). 
Mean age  76 years 
Male percentage 35% 
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Country USA 
Interventions  Patients randomised to the Heart Failure Monitoring System 
(HFMS) cohort received a disease management program using 
telecommunication equipment including an electronic scale 
and individualised symptom response system linked to a 
database staffed by nurses. Patients weighed themselves and 
answered questions related to their heart failure. Patients were 
contacted if any changes were observed in symptoms or 
weight. 
Patients allocated to standard heart failure care (SC) received 
enhanced patient education, education to clinicians and follow-
up. They were provided with a digital home scale to weigh 
themselves daily and educational materials related to 
worsening of HF and were asked to record heart failure 
symptoms. 
All patients were telephoned 30 days and  3 months post-
randomisation for blinded clinical data collection (vital signs, 
hospital visits, quality of life questionnaires). 
Outcomes Treatment failure (cardiovascular mortality or re-
hospitalisation for HF within 6 months), length of hospital 
stay, 6-month all-cause hospitalisation, 6-month heart failure 
hospitalisation, number of emergency room visits, Medicare 
expenditure, total patient costs, quality of life. 
Follow-up length  Six months 
Notes Number of patients hospitalised calculated from reported % 
with any hospital admission. 
 
Tibaldi V, 2009  
Participants 101 heart failure patients with NYHA class III-IV 
Mean age  81 years 
Male percentage 51% 
Country Italy 
Interventions  The inpatient control group received routine hospital care. 
Protocols for prevention of nosocomial infections, bed sores, 
and immobilization are routinely adopted for frail elderly 
inpatients. 
The intervention group included the patients treated at home 
by the Geriatric Home Hospitalization Service (GHHS). It 
provides substitutive hospital-at-home care in a clinical unit 
model and has been in operation for more than 20 years. The 
team, equipped with 7 cars, is multidisciplinary and consists of 
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4 geriatricians, 13 nurses, 3 physiotherapists, 1 social worker, 
and 1 counselor. The main feature of the GHHS is that 
physicians and nurses work together as a team, with daily 
meetings to discuss the needs of each patient and to organize 
individualized medical care plans. The team operates 7 days a 
week and on average cares for 25 patients per day and 450 
patients per year. The most common diseases treated at home 
are cardiopulmonary, cerebrovascular, metabolic, and 
neoplastic diseases. The GHHS can be activated by a direct 
request of the general physician of the patient as an alternative 
to traditional hospital care or by a request from hospital ward 
physicians to allow early and protected discharge from the 
hospital.   
Treatments included physician and nurse visits, standard blood 
tests, pulse oximetry, spirometry, electrocardiography, 
echocardiography, internistic echography and Doppler 
ultrasonography, ambulatory electrocardiography and arterial 
blood pressure monitoring, oral and intravenous medication 
administration (such as antimicrobials and cytotoxic drugs), 
oxygen therapy, blood products transfusion, central venous 
access, surgical treatment of pressure sores, physical therapy, 
occupational therapy, and counseling.  
Outcomes Mortality, hospitalization 
Follow-up length  6 months 
Notes  
 
Woodend A K,  2008  
Participants 121 patients with symptomatic heart failure (NYHA Class II or 
greater). 
Mean age  68 years 
Male percentage 74% 
Country Canada 
Interventions  Daily transmission of weight and periodic transmission of 
ECG and BP. Weekly video conferences by tele-home care 
nurse. Video conferences more frequent in first few weeks and 
tapered over the 3 months. 
Usual care was not described. 
Outcomes Mortality, rehospitalisation, quality of life, emergency 
department visits, patient satisfaction. 
Follow-up length  12 months 
Notes Mortality data included in previous systematic review and 
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meta-analysis Clark 2007a. 
 
2.3 Disease Management Program versus Home-monitoring 
A wide literature investigates effects of HM or DMP on clinical outcomes 
of patients suffering from CHF[5-14]. In almost the totality of study, those 
models have been compared to ambulatory follow up, which is considered 
the usual care (benchmark) as it is recommended by international 
guidelines[20]. Nonetheless, there is not wide literature that compares 
directly costs and outcomes of HM and DMP[15-17]. Nonetheless, this 
comparison is needed since many National Health Services, in particular 
the Italian one[18], are starting considering Home-monitoring to overcome 
usual care, but although there is strong evidence that HM overcomes DMP, 
there is a preliminary study proving that HM are more costly (up to five 
times) than DMP[19]. 
2.3.1 Meta-analysis for comparison of the efficacy 
For each outcome, two independent meta-analysis were performed in order 
to compare DMP with UC and HM with UC, respectively. In both meta-
analyses, continuous outcomes were expressed by Mean Differences, with 
the relative 95% Confidence Interval; binary outcomes were expressed by 
Relative Risks, with the relative 95% Confidence Interval. The 
heterogeneity was assessed by using the Chi-square Test and a p-value less 
than 0.05 was considered statistically significant. When the heterogeneity 
test was statistically significant, the Random Effect Model was adopted, 
otherwise the fixed-effects models[23]. 
The software Meta-Analyst was used to process data[24]; the results were 
represented by forest plots, while funnel plots were examined because of  
the potential of publication bias. Finally, effect size of DMP and HM was 
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assessed using network meta-analysis[25]. To assess the variation between 
studies, I used the statistic Chi-squared as the difference of the overall 
heterogeneity and the measures of  the heterogeneity in the two primaries 
meta-analyses[26]. 
2.3.1.1 Network meta-analysis 
The Network Meta-analysis (NM) is a method for indirect comparison of 
two or more treatments, when the available evidence consists of a network 
of multiple RCTs involving treatment compared directly or indirectly or 
both[27]. While traditional meta-analysis provides a direct comparison 
using studies comparing the same intervention with the same comparator 
(for instance, placebo or gold standard), NM enables multiple pair-wise 
comparison across several interventions and provides estimates of relative 
treatment effect on multiple comparative comparisons. 
NM could be applied to network of RCTs of different complexities. In the 
current thesis, it was applied to the simplest network of RCTs, in which g 
studies compared the treatment A with the control C and h studies 
compared the treatment B with the control C, and the NM enables the 
indirect comparison between A and B. In the case study, Home-monitoring  
and Disease Management Programs represents the treatments A and B, 
respectively, while the Usual Care represents the control C. In this case (in 
which the network does not consist of loop), two tradition meta-analyses 
were performed to directly compare treatment A versus C and treatment B 
versus C, and then, the results were pooled according to the methodology 
of NM proposed by Bucher[26] and described also by [28].  
2.3.2 Research strategy 
From previously published meta-analysis about DMP and HM for patients 
affected by heart failure [5-14], the research was restricted to randomized 
controlled trials (RCTs) published in English peer-reviewed literature; no 
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restriction on publications dates was applied. An electronic search in the 
MedLine’s and the Cochrane’s Databases was performed considering the 
following keywords, in combination with the boolean operators And/Or:  
o heart failure;  
o disease management program;  
o usual care;  
o home-monitoring;  
o telemonitoring; 
o structured telephone service.  
The aim was to find RCTs comparing Chronic Heart Failure management 
delivered via disease management programs or via home-monitoring with 
usual post-discharge care in patients with CHF living within community.  
A study was excluded if: 
o the follow-up was shorter than 6 months or longer than 18 months; 
o its aim was not coherent with the current study (for instance, it make 
a comparison between DMP and HM or did not provide outcome of 
interest in an extractable form); 
o it reported redundant or incomplete data (for instance, multiple 
publication of the same RCT); 
o its full-text was not in English language; 
o it reported data of a three arms randomized controlled  trials. 
For the purpose of the current research, three strategies of care were 
idenfied: usual care, disease management program (without the support of 
technology), technology-assisted home monitoring program. 
For the purpose of this study, the following definition was adopted: 
o Usual Care, further referred as UC, consists of standard post-
discharge care without intensified attendance at cardiology clinics or 
clinic-based CHF disease management program or home visiting[5]; 
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o Disease Management Program (without the support of technology), 
further referred as DMP, consists of coordinated and 
multidisciplinary healthcare intervention and communication6. DMP 
may include a telephone monitoring approach including regularly 
scheduled structured telephone contacts between patients and health 
care providers (with or without home visits) and reporting of 
symptoms and/or physiological data[10]; 
o Technology-assisted Home Monitoring program, further referred as 
HM, is the model  in which the DMP is integrated by remote 
monitoring of signs, symptoms, physiological parameters, and 
biomedical signals. For that reason, it includes a strong adoption of 
information and communication technology (ICT) [10]. 
All the full-text were independently analyzed by two investigators (PM - 
the author of the thesis and Dr Leandro Pecchia LP – the co-supervisor of 
the thesis) in order to classify the strategies proposed by the RCT as UC, 
DMP or HM and independently extracted the data from the included 
studies. A third reviewed (Prof. Marcello Bracale MB – the supervisor of 
the thesis) adjudicated in the instance of disagreement between the first two 
investigators and checked all the extracted data. 
84 RCTs matched the research strategy: 18 [29, 30] of them were not fully 
coherent with the aim of this Study; 10 papers [16] reported redundant or 
insufficient data; 9 papers [31] were excluded as they did not report data 
about of follow-up durations between 6 and 18 month; 3 [32] were not in 
English language; 2 were three arms RCTs which provided data about UC, 
DMP and TM. Thus, 42 studies were included, of which 31 RCTs 
compared DMP and UC and 11 compared  HM and UC.  Table 3 reports 
the excluded studies and the relative reason of exclusion. 
Table 3: List of excluded studies and relative motivation 
First Author, Year Motivation for exclusion 
Aiken LS, 2006 [29] not coherent with the objective  
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First Author, Year Motivation for exclusion 
Albanese MC, 2001 [32] paper not in English language 
Barth V, 2001 [31] duration of follow-up not within 6-18 month 
Beckers PJ, 2010 [30] not coherent with the objective 
Benatar D, 2003 [16] redundant or incomplete data 
Capomolla S,  2002 [33] not coherent with the objective 
Capomolla S, 2004 [34] redundant or incomplete data 
Carrington MJ, 2010 [35] not coherent with the objective 
Chang BH, 2005 [36] not coherent with the objective 
Clark R A, 2007 [37] not coherent with the objective 
Cleland J G, 2005 [15] RCTs in three arms 
Evans, RS, 2010 [38] not coherent with the objective 
Fabbri G, 2007 [39] paper not in English language 
Fulmer TT, 1999 [17] RCTs in three arms 
Grancelli H, 2003 [40] redundant or incomplete data 
Harrison M B, 2002 [41] duration of follow-up not within 6-18 month 
Jenkins R L, 2001 [42] not coherent with the objective 
Jerant A F, 2001 [43] duration of follow-up not within 6-18 month 
Kielblock B,  2007 [44] paper not in English language 
Koehler F, 2010 [45] not coherent with the objective 
Laramee A S, 2003 [46] duration of follow-up not within 6-18 month 
McDonald K, 2001 [47] duration of follow-up not within 6-18 month 
McDonald K, 2002 [48] duration of follow-up not within 6-18 month 
Murray, 2004 [49] not coherent with the objective 
Nahm E S, 2008 [50] not coherent with the objective 
Naylor M,  1999 [51] redundant or incomplete data 
Naylor M,  1994 [52] duration of follow-up not within 6-18 month 
Naylor M,  1999 [53] redundant or incomplete data 
Peters-Klimm, 2008 [54] not coherent with the objective 
Prescott E, 2009 [55] redundant or incomplete data 
Ramachandran,2007 [56] not coherent with the objective 
Rich M W, 1995 [57] duration of follow-up not within 6-18 month 
Schwarz K A, 2008 [58] duration of follow-up not within 6-18 month 
Smeulders ES, 2009 [59] not coherent with the objective 
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Stewart S,  1998 [60] redundant or incomplete data 
Stewart S, 1999 [61] redundant or incomplete data 
Stewart S, 1999 [62] redundant or incomplete data 
Varma S,  1999 [63] not coherent with the objective 
Villani A, 2007 [64] not coherent with the objective 
Wakefield B,  2008 [65] redundant or incomplete data 
Whitten, 2007 [66] not coherent with the objective 
Zugck C, 2005 [67] not coherent with the objective 
 
Table 4 reports the list of included studies. 
 
Table 4: list of included studies 
First Author, Year Comparison 
Antonicelli R,  2008 [68] RCT comparing HM and UC 
Atienza F, 2004 [69] RCT comparing DMP and UC 
Balk A H,  2008 [70] RCT comparing HM and UC 
Blue L, 2001 [71] RCT comparing DMP and UC 
Bourge R C, 2008 [72] RCT comparing HM and UC 
Bouvy M L,2003 [73] RCT comparing DMP and UC 
Cline C M,  1998 [74] RCT comparing DMP and UC 
de Lusignan S 2001 [75] RCT comparing HM and UC 
DeBusk R F,  2004 [76] RCT comparing DMP and UC 
DeWalt D A 2006 [77] RCT comparing DMP and UC 
Doughty R N, 2002 [78] RCT comparing DMP and UC 
Dunagan W C, 2005 [79] RCT comparing DMP and UC 
Ekman I,  1998 [80] RCT comparing DMP and UC 
Galbreath A D,  2004 [81] RCT comparing DMP and UC 
Gattis W A,  1999 [82] RCT comparing DMP and UC 
Giordano A,  2009 [83]  RCT comparing HM and UC 
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Goldberg L R, 2003 [84] RCT comparing HM and UC 
Hughes S L, 2000 [85] RCT comparing DMP and UC 
Jaarsma T, 1999 [86] RCT comparing DMP and UC 
Kashem A, 2008 [87] RCT comparing HM and UC 
Kasper E K, 2002 [88] RCT comparing DMP and UC 
Krumholz H M, 2002 [89] RCT comparing DMP and UC 
Mejhert M,  2004 [90] RCT comparing DMP and UC 
Mortara A, 2009 [91] RCT comparing HM and UC 
Naylor M D, 2004 [92] RCT comparing DMP and UC 
Peters-Klimm F, 2010 [93] RCT comparing DMP and UC 
Philbin E F, 2000 [94] RCT comparing DMP and UC 
Rainville E C 1999 [95] RCT comparing DMP and UC 
Rich M W, 1993 [96] RCT comparing DMP and UC 
Riegel B, 2002 [97] RCT comparing DMP and UC 
Riegel B, 2006 [98] RCT comparing DMP and UC 
Sisk J E, 2006 [99] RCT comparing DMP and UC 
Soran O Z, 2008 [100] RCT comparing HM and UC 
Stewart S 2002 [101] RCT comparing DMP and UC 
Stromberg A, 2003 [102] RCT comparing DMP and UC 
Thompson DR, 2005 [103] RCT comparing DMP and UC 
Tibaldi V, 2009 [104] RCT comparing HM and UC 
Tsuyuki R T, 2004 [105] RCT comparing DMP and UC 
Wakefield B J,2008 [106] RCT comparing DMP and UC 
Weinberger M,  1996 [107] RCT comparing DMP and UC 
Woodend A K,  2008 [108] RCT comparing HM and UC 
Young W, 2003 [109] RCT comparing DMP and UC 
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2.3.3 Identified Outcome 
From the results of previously published meta-analysis[3, 5-14] and of our 
research, the following outcomes were selected:  
1. all-cause cause mortality; 
2. HF-related mortality; 
3. number of patients readmitted for all causes; 
4. number of patients readmitted for HF-related causes; 
5. bed-days of care for all causes; 
6. bed-days of care for HF-related causes. 
2.3.4 Results of the comparison 
All cause mortality data were available from 24 studies comparing DMP 
with UC (Figure 1) and 7  studies comparing HM with UC (Figure 2). I 
found that DMP and HM were related to a lower number of death for all 
causes compared with the UC (RR=0.86, 95%IC=0.73, 1.01;  RR=0.62, 
95% IC=0.45, 0.84; respectively) but the effect size was significant only 
for HM. 
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Figure 1: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on risk of all-cause mortality compared with Usual Care 
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Figure 2: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on risk of all-cause mortality compared with Usual Care 
HF-related mortality data were available from 5 studies comparing DMP 
with UC (Figure 3) and 2 studies comparing HM with UC (Figure 4). Both 
DMP and HM were related to a reduction of HF related mortality 
(RR=0.67, 95%IC=0.43, 1.04;  RR=0.60, 95%IC=0.37, 0.98; respectively), 
but the effect size was significantly only for HM. 
 
Figure 3: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on risk of HF-related mortality compared with Usual Care 
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Figure 4: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on risk of HF-related mortality compared with Usual Care 
Data regarding the number of patients readmitted for all causes were 
available from 15 studies comparing DMP with UC (Figure 5) and from 3 
studies comparing HM with UC (Figure 6). Comparing DMP or HM to 
UC, I did not find a statistical statistically significant differences for this 
outcome (RR=0.96, 95%IC=0.87, 1.07;  RR=0.80, 95%IC=0.51, 1.25; 
respectively). 
HF-related hospitalization rate data were available from 15 studies 
comparing DMP with UC (Figure 7)  and from 4 studies comparing HM 
with UC (Figure 8).  
Both DMP and HM was related to a significantly lower number of patients 
readmitted for HF (RR=0.70, 95%IC=0.55, 0.90;  RR=0.71, 95% IC=0.53, 
0.97; respectively) 
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Figure 5: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on all-cause readmission rate compared with Usual Care 
 
 
Figure 6: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on all-cause readmission rate compared with Usual Care 
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Figure 7: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on HF-related readmission rate compared with Usual Care 
 
Figure 8: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on HF-related readmission rate compared with Usual Care 
 
All cause bed days of care data were available from 15 studies comparing 
DMP with UC (Figure 9) and from 4 studies comparing HM with UC 
(Figure 10). Comparing DMP or HM to UC, I did not find a statistical 
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statistically significant differences for this outcome (MD=-1.09, 95%IC=-
2.70, 0.53;  MD=-0.12, 95%IC= -1.63, 1.40; respectively).  
 
Figure 9: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on numbers of all-cause bed days of care compared with 
Usual Care 
 
 
Figure 10: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on numbers of all-cause bed days of care compared with Usual Care 
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HF-related bed days of care data were available from 6 studies comparing 
DMP with UC (Figure 11) and 3 studies comparing HM with UC (Figure 
12). Comparing DMP or HM to UC, I did not find a statistical statistically 
significant differences for this outcome (MD: -1.03, 95% IC: -3.90, 1.85;  
MD=-0.35, 95%IC=-2.02,1.32; respectively). 
 
Figure 11: impact of Disease Management Programs of patients suffering from 
Chronic Heart Failure on numbers of HF-related bed days of care compared with 
Usual Care 
 
Figure 12: impact of Home-monitoring of patients suffering from Chronic Heart 
Failure on numbers of HF-related bed days of care compared with Usual Care 
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Table 5 summarizes the results of the direct comparisons between DMP 
and UC, and HM and UC for the binary outcomes and shows the results of 
the network meta-analysis for the indirect comparison between DMP and 
UC (see last column). No statistically significant differences between DMP 
and HM for the binary outcomes was found.  
Table 5: Comparison of Relative Risk (RR) between Disesase Management 
Programs (DMP) and Usual Care (UC), Home-Monitoring (HM) and Usual Care, 
and Home-Monitoring and Disease Management Programs for each selected 
binary outcome 
Binary outcomes 
DMP vs UC 
RR (95%IC; p) 
HM vs UC 
RR (95%IC; p) 
HM vs DMP 
RR (95%IC; p) 
All-cause mortality 
0.86 (0.73, 1.01; 
p>0.05) 
0.62 (0.45, 0.84; 
p<0.05) 
0.72 (0.51, 1.01; 
p>0.05) 
HF-related mortality 
0.67 (0.43, 1.04; 
p>0.05) 
0.60 (0.37, 0.98; 
p<0.05) 
0.90 (0.46, 1.52; 
p>0.05) 
# of patients readmitted 
for all causes 
0.96 (0.87, 1.07; 
p>0.05) 
0.80 (0.51, 1.25; 
p>0.05) 
0.83 (0.57, 1.22; 
p>0.05) 
# of patients readmitted 
for HF 
0.70 (0.55, 0.90; 
p<0.05) 
0.71 (0.53, 0.97; 
p<0.05) 
0.83 (0.57, 1.22; 
p>0.05) 
 
Table 6 summarizes the results of the direct comparisons between DMP 
and UC, and HM and UC for the continuous outcomes and shows the 
results of the network meta-analysis for the indirect comparison between 
DMP and UC (see last column). No statistically significant differences 
between DMP and HM for the continuous outcomes was found. 
Table 6: Comparison of Mean Difference (MD) between Disease Management 
Programs (DMP) and Usual Care (UC), Home-Monitoring (HM) and Usual Care, 
and Home-Monitoring and Disease Management *Programs for each selected 
binary outcome 
Continuous Outcomes 
DMP vs UC 
MD  
(95%IC; p) 
HM vs UC 
MD  
(95%IC; p) 
HM vs DMP 
MD  
(95%IC; p) 
Bed days of care  
for all causes 
 
-1.09  
(-2.71, 0.53; 
p>0.05) 
 
-0.12  
(-1.63, 1.40; 
p>0.05) 
 
0.97  
(-0.70, 2.61; 
p>0.05) 
 
Bed days of care  
for HF 
-1.03  
(-3.90, 1.85; 
p>0.05) 
-0.35  
(-2.02, 1.32; 
p>0.05) 
0.68  
(-2.0, 3.36; 
p>0.05) 
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2.4 Discussion and conclusion 
From the results presented in this chapter, it emerged that HM significantly 
reduced mortality, either for all-causes either for HF-related causes, and 
number of patients readmitted for HF-related causes, while DMP 
significantly reduced number of patients readmitted for HF-related causes.  
These results confirms those of previously published meta-analyses about 
―disease management programs‖[9, 14], ―structured telephone support‖ and 
―Telemonitoring‖[5, 8, 10, 12, 13] in showing the effectiveness of these 
strategy compared to UC in order improving the main clinical outcome. For 
instance, the results about all-cause mortality are in line with the findings 
of the recent meta-analyses by Inglis[5] comparing Structured telephone 
support programs with UC and Telemonitoring programmes with UC. I 
underlined that almost all ―structured telephone support‖ programs of these 
reviews were classified as DMP for the purpose of the current study, while 
almost all ―Telemonitoring‖ ones were included among the HM strategy.  
Moreover, the current study compared HM to DMP using a Network Meta-
analysis, which enables an indirect comparison between the two models of 
care in spite of the lack of a sufficient number of RCTs which would 
enables a direct comparison. The results of the indirect comparison showed 
that there is not significant evidence that HM overcomes DMP. 
Nonetheless, the indications of effect size reported in Table 5 and in Table 
6 seems to confirm the conclusions of the few available RCTs[17], which 
stated that HM improved DMP even if the difference was not always 
statistically significant. In particular, Benatar[16] showed that readmission 
rate at 6 months was significantly lower in the TM compared with the DMP 
group. Results by Cleland [15] showed that all-cause mortality was reduced 
by both strategies compared with UC but no significant differences were 
observed between HM and DMP in the primary or secondary outcomes 
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selected. Similarly, no significantly statistical difference was reported by 
Fulmer [17]. 
The main limit of the results shown in this chapter is the fewer number of 
RCTs considering TM than those considering DMP. Since, given the 
weight of evidence, further RCTs of ―structured telephone support‖ and 
―Telemonitoring‖ in comparison of usual care were not recommend, I 
suggest that RCTs comparing strategy of care with different intervention 
intensity should be performed in order to enable a direct comparison. 
In conclusion, an indirect comparison of Home Monitoring and Disease 
Management Programs was performed by a network meta-analysis of 
randomized controlled trial comparing HM or DMP with usual care. Both 
strategies of care improved significantly some clinical outcomes compared 
to usual care, for instance the number of patients readmitted for Heart 
Failure. The indirect comparison showed that there was no significant 
difference in the effect size for the selected outcomes.   
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3. Enhancement of Telemedicine service with 
Data-Mining: CHF detection and assessment 
 66 
3.1 Description of the telemedicine plaftorm developed for the 
Project Remote Health Monitoring 
In this chapter, I present the system developed for Remote Health 
Monitoring (RHM) of patients suffering from Heart Failure, which includes 
advanced functionalities of data-mining for continuous patient monitoring. 
The clinical goal was the early detection of any worsening in patient’s 
condition, with automatic ―HF severity assessment‖ using data-mining, 
assuming that during worsening, patients will gradually show characteristic 
of a more severe HF. The system was developed in the last three years. 
First, I described briefly the whole platform developed for the Project 
Remote Health Monitoring I contribute to design and develop, then I 
present the methods employed and to present the preliminary results of the 
data mining for HF detection and severity assessment. The results 
described were obtained testing the system with biomedical signals from 
public databases, in order to allow other scientists to reproduce them, and 
because results clinical trials involving local patients were not available at 
the time of writing the current chapter. 
3.2 Description of the platform 
The system designing followed the so-called ―Three Tier architecture‖. 
Functionally, the platform consisted of three parts, called ―Areas‖: ―Client 
Area‖ (CA) acting as presentation tier, ―Server Area‖ (SA) as business tier 
and data tier and the ―Web Service Area‖ (WSA) as pure business tier 
level. The CA aimed to present and to collect data using devices, which 
differed according to the users and the scenarios. The SA aimed to manage, 
store and retrieve data and included the Electronic Patient Record (EPR) 
and an Interactive Voice Response (IVR)[110], which acted as audio user 
interface. The WSA was used for raw data processing, signal analysis and 
data mining. IVR allowed users less skilled with web technologies to insert 
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daily ECG records and physiological parameters (pressure, weight and 
temperature). The IVR, after a login, gave the user all the instructions and 
recommendations to send data, repeating, when possible, the entered values 
and asking for further confirmation. 
The devices tested and integrated in the system, varied according to the 
scenario, going from user-friendly ones for self-recording of signals/signs 
to professional multi-parametric monitors, recording ECG, blood pressure 
(BP), hart rate (HR), SpO2, temperature (T), Galvanic Skin Response 
(GSR), skin near-body temperature (ST), respiratory frequency (RF), 
Activity (A) and Posture (P).  
According to the scenario, the software/hardware and the communication 
line to allow data sending also varied. The RHM platform was tested in 
three different scenarios: home care, medical ambulatory and hospital.  
3.3 Data-mining application 
The platform supported a strategy of automatic classifications consisting of 
two steps: ―HF detection‖ and ―HF severity assessment‖. The former was 
used in the platform to pre-screen patients before they underwent the latter. 
The whole classification aimed to early detection of any worsening, 
assuming that during worsening, patients will gradually show characteristic 
of a more severe HF. Both classifiers were based on the Classification and 
Regression Tree method. Although the system collected several data, at the 
moment only features obtained from ECG records were adopted for the 
data-mining functionalities. 
3.3.1 Classification and Regression Tree 
The CART is an algorithm to develop classification trees from the top 
down using a process known as binary recursive partitioning. It consists of 
two steps: tree growing and tree pruning.  
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The former step is an iterative process in which the data are split repeatedly 
into groups, called as child nodes. The split is based on a single variable 
and can be expressed by a if-then rule: ―if selected-feature-value is  higher 
than cut-off-value, then go into child node 2, else go into child node 1‖. 
Among possible splits, those which generate the ―purer‖ child nodes, where 
the purest node is the one containing elements of only one class. Among 
different functions that have been proposed for the measure of the impurity 
of each node ―t‖[111], I adopted the Gini index criterion, which, for binary 
classification, can be computed  as follows:   
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(1) 
where ―t‖ is the considered node, ―i‖ and ―j‖ are the two class labels, ―ni‖ 
and ―nj‖ are the number of subject present at the node belonging to the 
class ―i‖ or ―j‖, respectively, and n is the number of subject present at the 
node. The tree growing stops when no further split is possible and the 
outcome of this step is referred to as the Large-Tree (LT). 
In the latter step, the tree is pruned, according to a minimal cost-complexity 
function, which relies on the size of the tree (number of nodes) and the 
misclassification probability (MP). I estimated the MP performing a 10-
fold-crossvalidation.  This technique consists in developing 10 trees as 
following: (1) dividing randomly the dataset into 10 subsamples; (2) 
excluding a subsample (testing subset) in turn; (3) developing each tree 
with the remaining 9 subsamples (training subset); (4) testing each tree 
with the excluded subsample (which is used as an independent testing 
dataset), computing the ratio of misclassified cases (mpi). The MP of the 
tree is the average over the 10 ratios of misclassified cases mpi. I decided to 
divide the data-set by subjects and not by records, as two records of the 
same subject could not be considered as independent. 
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Further details on CART growing and pruning can be found in Breiman 
[111].  
3.3.2 Data 
The results described in this chapter were obtained testing the system with 
biomedical signals from public databases, in order to allow other scientists 
to reproduce them, and because results from clinical trials involving local 
patients were not available at the time of writing the current chapter. 
The dataset consisted into 116 nominal 24-hour records, from 72 normal 
subjects and 44 suffering from CHF. The overall dataset consisted of 54 
men, 43 women and 19 unknown-gender subjects, aged 20 to 79 (55±14 
years). The normal subjects were 35 men and 37 women, aged 20 to 76 
(55±16 years). The CHF subjects were 19 men, 6 women and 19 unknown-
gender subjects, aged 22 to 79 (56±11 years).  
The data for normal subjects were retrieved from the Normal Sinus Rhythm 
RR Interval Database [112] and from the MIT-BIH Normal Sinus Rhythm 
Database [112]. The former includes RR intervals extracted from 24-hour 
ECG recordings from 30 men and 24 women, aged 29 to 76 (61±12 years). 
The latter includes long-term ECG recordings from 5 men and 13 women, 
aged 20 to 50 (61±8 years). The data for the CHF group were retrieved 
from the Congestive Heart Failure RR Interval Database [112] and from the 
BIDMC Congestive Heart Failure Database [112]. The former includes RR 
intervals extracted from 24-hour ECG-Holter recordings of 8 men, 2 
women, and 19 unknown-gender subjects, aged 34 to 79 (55±11 years). 
The latter database includes long-term ECG recordings from 11 men and 4 
women, aged 22 to 71 (56±11 years), with severe congestive heart failure. 
All the records are provided with beat annotations obtained by automated 
analysis with manual review and correction, with the exception of beat 
annotations from the BIDMC Congestive Heart Failure Database which 
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were not manually corrected. All the original ECG records were digitized 
at 128 samples per second, with the exception of the records from the 
BIDMC Congestive Heart Failure Database, which were sampled at 250 
samples per second. 
3.3.3 Long-term HRV analysis 
Standard long-term HRV analysis was performed on nominal 24-hour 
recordings according to International Guidelines[113].  
The series of normal to normal (NN) beat intervals were obtained from the 
beat annotation files of the selected four databases and the NN/RR ratio 
was computed as the fraction of total RR intervals classified as normal-to-
normal (NN) intervals. This ratio has been used as a measure of data 
reliability, excluding records with a ratio less than a threshold. Thresholds 
of 80%[112]  and 90%[114] were proposed. I chose a threshold of 85%, as 
it was a satisfactory trade-off between numbers of included subjects and 
quality of NN signals. Using this technique, 6 records were excluded (5 
CHF and 1 normal) and the final dataset consisted of 110 subjects: 71 
healthy people and 39 CHF patients. 
All the computed basic time- and frequency-domain HRV measures were 
widely used in the literature[113, 115]. A number of standard statistical 
time-domain HRV measures are calculated: AVerage of all NN intervals 
(AVNN), Standard Deviation of all NN intervals (SDNN), Standard 
Deviation of the Averages of NN intervals in all 5-minute segments of a 
24-hour recording (SDANN), mean of the Standard Deviations of NN 
intervals in all 5-minute segments of a 24-hour recording (SDNN IDX),  
square Root of the Mean of the Sum of the Squares of Differences between 
adjacent NN intervals (RMSSD), percentage of differences between 
adjacent NN intervals that are  longer than  50 ms (pNN50). Moreover, 
percentage of differences between adjacent NN intervals that are  longer 
than 12 ms (pNN12) was computed because Mietus [116] showed that 
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among pNNx measures pNN12 can provide the maximum separation 
between normal subjects and CHF patients.  
The frequency-domain HRV measures rely on the estimation of power 
spectral density (PSD). Several methods were proposed in literature in 
order to estimate PSD of RR intervals [113, 115]. For this research, PSD 
were estimated by both by Welch’s averaged modified periodogram[117] 
and by Lomb-Scamble periodogram[118]. For the Welch’s periodgram, the 
NN interval was first interpolated with cubic spline interpolation at 4 Hz. 
The interpolated series was divided into overlapping segments of length 
4000 points and each segment was Hanning windowed. The overlap was 
chosen to be 1200 points[114]. After PSD estimation, six standard 
frequency-domain HRV measures were calculated: total spectral power of 
all NN intervals up to 0.4 Hz (TOTPWR), between 0 and 0.003 Hz (ULF), 
between 0.003 and 0.04 Hz (VLF), between 0.04 and 0.15 Hz (LF), 
between 0.15 and 0.4 Hz (HF), ratio of low to high frequency power 
(LF/HF). Further in this chapter, I will refer Welch-based measures and the 
Lomb-Scamble-based ones by using the subscript W and LS, respectively. 
For instance, TOTPWRW refers to the estimation of TOTPWR computed 
by using Welch periodgram, while TOTPWRLS refers to the one obtained 
by Lomb-Scamble periodgram. 
3.3.4 Heart Failure detection 
The results of the data-mining methods adopted consisted into a decision 
tree like those proposed in Figure 13 and Figure 14. These trees enables the 
automatic detection of Heart Failure.  
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Figure 13: The final model tree for the following HRV features:   
a) SDNN, b) SDANN, c) TOTPWRW 
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Figure 14: The final model tree for the following combinations of HRV features: 
a) TOTPWRLS, RMSSD, SDANN; b) VLFLS and pNN12 
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In Figure 13 and Figure 14 the paths from the first node to each terminal 
one are a graphical representation of a set of ―if … then‖ rules. For 
instance, the path to the terminal node 2 in the Fig. 2a can be read as: ―if 
TOTPWRLS is higher than 8271.86 ms
2
 and RMSDD is higher than 15.62 
ms, then the subject is classified as normal‖. 
In the models shown in Figure 13, if the selected feature (SDNN; SDANN; 
TOTPWRW) was lower than a threshold (93.892 ms; 76.869 ms; 6,313.239 
ms
2
, respectively), the subject was classified as a CHF patient, otherwise as 
a normal subject. 
In the model shown in Figure 14a, the initial variable selected by CART (at 
node 1 split) was TOTPWRLS . The subjects whose TOTPWRLS is lower 
than 8271.86 ms
2
 were correctly classified as CHF patient. CART selected 
RMSSD for the second node split. In this node split, the subjects whose 
RMSSD were higher than 15.62 ms were classified as normal. This 
splitting determined the four false negatives of the classifier. A final 
classification split is based on SDANN, that is, if it is lower than 106.71 
ms, the subject is classified as CHF patient, otherwise as a normal subject. 
In the model shown in Figure 14b, the initial variable selected by CART (at 
node 1 split) was VLFLS. The subjects whose VLFLS is lower than 558.048 
ms
2
  were correctly classified as CHF patient. CART selected pNN12 for 
the second node split. In this node split, the subjects whose pNN12 were 
lower than 36.466 were classified as CHF patients, the others as normal 
subject. This splitting determined the nine false negatives and the one false 
positive of the classifier. 
3.3.4.1 Performance measurement and comparison with previous 
studies 
In order to compare with previous similar studies, the common 
performance measure for binary classification were computed as reported 
in  Table 7 
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Table 7: Binary Classification Performance Measures 
Measure Abbreviation formula 
Accuracy Acc 
FNFPTNTP
TNTP

  
Precision Pre 
FPTP
TP

 
Sensitivity Sen 
FNTP
TP

 
Specificity Spe 
TNFP
TN

 
Area Under 
the Curve 
AUC ;2
1
 









FPTN
TN
FNTP
TP
AUC
 
TP:  number of CHF patients detected 
TN: number of normal subject detected 
FP: number of normal subject incorrectly labelled as CHF 
FN: number of CHF patients incorrectly labelled as normal. 
 
Table 8 shows the performance measures of the decision tree proposed in 
this research and of two classifiers proposed by other authors[114, 119]. 
 
Table 8: Classification Performance Measurements of the classifiers proposed in 
the current study and those proposed in previously published papers 
Classifier based on  
single feature 
TP 
# 
FN
# 
TN 
# 
FP
# 
ACC
% 
PRE
% 
SEN
% 
SPE
% 
AUC
% 
SDNN 34 5 69 2 93.6 94.4 87.2 97.2 92.2 
SDANN 32 7 71 0 93.6 100 82.1 100 91.0 
TOTPWRW 26 9 71 0 91.5 100 74.3 100 87.1 
Asyali [114](based on 
SDNN) 
18 4 51 1 93.2 94.7 81.8 98.1 89.9 
          
Classifier based on 
combination of features 
TP 
# 
FN
# 
TN 
# 
FP
# 
ACC
% 
PRE
% 
SEN
% 
SPE
% 
AUC
% 
TOTPWRLS, RMSSD, 
SDANN 
35 4 71 0 96.4 100 89.7 100 94.9 
VLFLS, pNN12 26 9 70 1 90.6 96.3 74.3 98.6 86.4 
Isler [119]* 29 0 51 3 96.4 90.6 100 94.4 97.2 
* based on short-term HRV measures 
 
In both these studies [114, 119] the classifiers were developed using a 
smaller dataset than in the current study, as they used only the MIT-BIH 
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Normal Sinus Rhythm Database [112] and the Congestive Heart Failure 
RR Interval Database [112]. 
The performance measures of our classifiers are higher than those of 
Asyali’s classifier[114], which used HRV long term measures. Asyali [114] 
identified SDNN  and SDANN as the HRV measures with the highest class 
separation power and the results in the current study confirm this 
identification. Moreover, our study showed that TOTPWRW is the third 
measure for separation power. This is not in line with Asyali’s findings 
[114], which showed that the TOTPWRW discrimination power is the 
second-last. This could be because Asyali used Fisher’s Linear 
Discriminant Analysis (LDA) without proving normal distribution of HRV 
features. In fact, LDA is strongly affected by non-normality of data [120] 
and for that reason is expected to provide less accurate information about 
no-normal measures, such as TOTPWR[121]. 
The performance measures of our classifier are lower than those of Isler’s 
classifier[119], which used HRV short-term measures. The best 
combination of features selected by Isler consists of 8 features including 
sex, FFT-based measures, LS periodogram measures and wavelet entropy 
measures with a sensitivity rate of 100.00% and a specificity rate of 
94.74%[119]. The higher sensitivity rate may be because of the 
discrimination power of wavelet entropy measures, which have not been 
considered in this study because they are not standard HRV measures, 
presumably too complex to understand for most clinicians. Moreover, 
Isler’s classifiers[119] were based on at least 8 features. 
As regards the chosen method, this improved intelligibility in comparison 
to Isler’s one [119] and minimized the risk of overfitting in comparison to 
Asyali’s one [114]. In fact, Isler[119] adopted k-nearest-neighbor (KNN) 
classifiers, which lack the property of the interpretability of induced 
knowledge [122]. While, Asyali [114] developed a Bayesian Classifier and 
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the classification is based on the following rule: ―a subject with an SDNN 
value higher (lower) than threshold topt is classified as normal (abnormal)‖. 
This rule is the same of the tree in Figure 14a, with a slightly different 
threshold: 93.89 for CART classifier, 91.82 for Bayes classifier. However, 
Asyaly computed the threshold on the whole dataset and provided no 
information about probability of misclassification, as he did not use cross-
validation approach nor independent test set. 
3.3.5 Heart Failure assessment 
The results of the data-mining methods adopted consisted into a decision 
tree like those proposed in. These trees enables the automatic assessment of 
Heart Failure.  
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Figure 15: The final model tree for the combination of HRV features: TOTPWRL, 
pNN50, pNN10, SDNNIDX 
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Figure 16: The final model tree for the combination of HRV features: ULF, 
TOTPWR, pNN50 
All the performance measures of these two BSTs, estimated both by 10-
fold-crossvalidation and by resubstitution, are reported in Table 9 and 
Table 10, respectively. 
Table 9: Classification performance measurements of the selected classifier 
estimated by 10-fold-cross-validation 
Classifier based on  
TP  
# 
FN  
# 
TN 
# 
FP 
# 
ME 
% 
ACC
% 
SEN 
% 
SPE 
% 
AUC 
% 
TOTPWR, pNN50, 
pNN10, SDNNIDX 
28 2 7 4 14.6 85.4 93.3 63.6 78.5 
ULF, TOTPWR, PNN50 28 2 7 4 14.6 85.4 93.3 63.6 78.5 
ALL FEATURES 29 0 0 11 27.5 72.5 100 0.0 50.0 
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Table 10: Classification performance measurements of the selected classifier 
estimated by resubstitution 
Classifier based on  
TP  
# 
FN  
# 
TN 
# 
FP 
# 
ME 
% 
ACC 
% 
SEN 
% 
SPE 
% 
AUC 
% 
TOTPWR, pNN50, 
pNN10, SDNNIDX 
29 1 11 0 2.4 97.6 96.7 100 98.3 
ULF, TOTPWR, PNN50 30 0 9 2 4.9 95.1 100 81.8 90.9 
ALL FEATURES 29 0 0 11 27.5 72.5 100 0.0 50.0 
3.4 Discussion and Conclusion 
In this chapter, I present the results about the discrimination power of 
standard long-term Heart Rate Variability (HRV) measures for the 
detection of Chronic Heart Failure. I analyzed single features and all their 
possible combinations.  It was indicated that the combinations of standard 
long-term HRV measures TOTPWRLS, RMSSD, and SDANN  enable 
distinguishing normal subjects from CHF patients with specificity and 
sensitivity rates of 100% and 89.74% respectively. The combination of 
pNN12 and VLF confirms the discrimination power of pNN12 proved by 
Mietus [116]. The sets of rules of the proposed models are clinically 
consistent, even if CART did not use any medical a priori knowledge. In 
fact, the main clinical result of this research is that terminal node 
classifying as CHF patients are on the left, therefore revealing lower values 
of the splitting features for CHF patients. This is coherent with the results 
showed by Bigger [123], Musialik-Lydka [124]  and Arbolishvili [125], 
who stated that standard long-term HRV measures were significantly 
depressed in CHF patients, compared with normal subjects. It should be 
emphasized that the findings of Bigger [123] and Arbolishvilli [125] were 
obtained adopting different methods for power spectral density estimation, 
while Musialik-Lydka [124] considered only time-domain HRV measures. 
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Also, the sets of rules of the models for HF assessment are clinically 
consistent, even if CART does not use any medical a priori knowledge.  
In fact, the main clinical result of the research about HF assessment is that 
terminal node classifying as HRPs are on the left, therefore revealing lower 
values of the splitting features for severe CHF patients (with the only 
exception of pNN50). This is coherent with the results showed by Casolo 
[126], Panina [127] and Arbolishvili. It should be emphasized that the 
findings of Casolo [126], Panina [127] and Arbolishvili [125] were 
obtained adopting different methods for power spectral density estimation. 
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4. Data-mining a data-warehouse for 
hypertensive patients 
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4.1 Background 
Cardiovascular (CV) diseases are considered one of the most important 
causes of morbidity and mortality in high developed countries. At this 
regard,  it is important to remember that there is a preclinical and 
asymptomatic period in which CV diseases can be detected by evaluating 
target organ damage at cardiac, vascular and renal level and earlier I find 
CV involvement easier I am able to influence the progression of the disease 
by therapy. 
Indeed, despite there is still a little information on the specific causes of 
these pathologies, it is well known that some physiological or pathological 
conditions (Sympathetic Drive) are more frequently related to CV 
involvement and to CV events. Analysis of heart period variability (HRV) 
on the basis of routine
 
24-hour Holter recordings has been shown to 
provide a sensitive,
 
noninvasive measurement of cardiac autonomic control. 
Until now clinical studies
 
have shown reduced heart period variability in 
patients with chronic
 
heart failure, diabetes, and ventricular arrhythmias; 
moreover,
 
decreased indexes of heart period variability have been shown
 
to 
be an independent risk factor for mortality in patients after
 
myocardial 
infarction. By this method, a sympatho-vagal
 
imbalance as evaluated by 
HRV (Heart Rate Variability) with increased sympathetic activity and 
reduced vagal
 
tone has been reported in patients with borderline 
hypertension
 
as well as in hypertensive patients but no data are present in 
literature on the relation of HRV and different cardiovascular involvement  
(i.e. cardiac, vascular and  renal) and its relationship with their progression 
and/or regression. 
Furthermore, several studies have shown that incidence of CV events can 
be reduced by therapeutic correction of any of modifiable risk factors, such 
as hypertension, LDL cholesterol plasma level, diabetes, smoking habit, 
physical inactivity increase incidence of coronary artery disease. On the 
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other hand few data are present in the literature on the effect of influence of 
HRV and the development and progression of CV disease and/or  reducing 
CV risk. 
The aim of this chapter was to show the evaluation of the correlation of 
HRV with asymptomatic development of CV disease at vascular, cardiac 
and renal level in hypertensive treated patients. 
4.2 Methods 
4.2.1 Population study 
For the present study, among the initial cohort of 12,000 outpatients 
scheduled in the database of the Campania Salute Network, I selected and 
recruited all the hypertensive subjects referred to the Hypertension Clinic 
of the ―Federico II‖ University of Naples from January 2000 which were 
evaluated by cardiac and  carotid ultrasonography and by an 24h Holter 
ECG and which meet the inclusion criteria. Details on this cohort have 
been previously described in some papers [128, 129]. Briefly, the 
Campania Salute network is an open registry collecting information from a 
network of general practitioners and community hospitals networked with 
the centre, and providing patients with a centralized data-base including 
demographics and clinical information. 
Exclusion criteria for the present analysis were: diagnosis of secondary 
resistant and/or uncontrolled hypertension, prevalent CV disease, clinical 
history of cancer, liver cirrhosis and/or failure, narcotics abuse, lifestyle 
changes in the last 12 months. Prevalent CV disease was excluded by an 
ad-hoc committee in the Hypertension Centre, based on patient’s history, 
contact with the referring general practitioner and clinical records 
documenting the occurrence of disease. Prevalent CV disease was defined 
as history of previous myocardial infarction or angina or procedures of 
coronary revascularization, stroke or transitory ischemic attack, congestive 
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heart failure at the time of the first examination in the outpatient clinic. 
Thus, the present analysis included 200 hypertensive participants aged 
from 25 to 88 years  (36.5 % women, mean age 62.4±12 yrs), free of 
prevalent CV disease, who were referred to the Hypertension Clinic of the 
―Federico II‖ University of Naples. 
The data-base generation of the Campania Salute Network was approved 
by the Federico II University Hospital Ethic Committee. Signed informed 
consent for used data for scientific purposes was obtained from all the 
participant. 
4.2.2 Protocol 
At the first visit all patients were given a detailed questionnaire inquiring 
about specifics lifestyle behaviours and smoking habit, in the current study 
they were categorized as non-smokers, ex-smorkers or smokers.  
BP values, clinical, biochemical and ultrasounds parameters were analyzed 
and recorded at the first visit and during the screening period.   
All patients underwent multiple clinical visits and performed baseline and 
follow-up Echocardiogram and Carotid Ultrasound procedure.  
Medical history, physical examination, routine laboratory tests and other 
diagnostic procedures of the patients were stored in a computerized 
database. 
4.2.3 Measurements and definitions 
During the visits, blood pressure, lipid and glucose profile were measured 
for each patient by standard methods. 
Diagnosis and stratification of essential hypertension was performed 
according to the criteria established by the Guidelines for the Management 
of Arterial Hypertension. 
Systolic and diastolic blood pressure were measured by standard aneroid 
sphygmomanometer after 5 min rest in the supine position, according to the 
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current guidelines[130]. Three blood pressure measurements were obtained 
in the sitting position at 2-min intervals. The averages of these 
measurements were used for the analysis.  
4.2.4 Laboratory Assessment  
Serum creatinine, fasting plasma glucose, total-cholesterol, and 
triglycerides were measured with the standard methods. Glomerular 
filtration rate (GFR) was calculated by the Modification of Diet in Renal 
Disease formula[131].  Diabetes was defined as a fasting blood glucose 
≥126 mg/dL or active glucose-lowering therapy[132]. 
4.2.4.1 Echocardiography  
Two-dimensional-guided M-mode echocardiograms were performed using 
a dedicated ultrasound machine (SONOS 5500, Philips) with an ultrasound 
transducer of 2.5 MHz. The examinations were recorded on a digital 
recorder and analysed by three independent, trained and experienced 
physicians. The parameters relative to the left ventricle (LV) were 
obtained, according to the criteria of the American Society of 
Echocardiography [133], each as an average of at least three measurements. 
LV mass was determined by using the formula developed by Devereux and 
Reichek [134] and divided by the body surface area to calculate LV mass 
index (LVMi, g/m
2
). Echocardiograms were recorded in videotapes, using a 
standardized protocol, were  digitally mastered and read off line by one 
expert reader under the supervision of a senior faculty member. 
Measurements were made according to [135].  
4.2.4.2 Carotid Ultrasound 
B-mode ultrasonography of carotid arteries was performed with patients in 
the supine position with the neck extended in mild rotation. The scanning 
protocol was performed with an ultrasound device (SONOS 5500, Philips) 
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equipped with a 7.5-MHz high-resolution transducer with an axial 
resolution of 0.1 nm. Examinations were recorded on S-VHS videotapes. 
All measurement were analysed by three different trained experienced 
physicians. An average of two readings were considered for subsequent 
calculations. The accuracy of determinations was evaluated as previously 
described by Lembo et al. [136]. The maximum arterial IMT (IMT max) in 
up to 12 arterial walls, including the right and the left, near and far distal 
common carotid (1 cm), bifurcation, and proximal internal carotid artery 
were estimated offline with an image processing workstation. 
4.2.5 Assessment of target organ damage 
Cardiac Involvement was evaluated as Left Ventricular Hypertrophy 
(LVH) which was diagnosed if LVMi exceeded 110 g/m
2
 in female and 
125 g/m
2
 in male[137]. Intraoperator and interassay variability were 5% 
and 6%, respectively [138] 
Vascular Involvement was assessed as Carotid artery atherosclerosis as an 
increased intimal plus medial thickness (IMT) by B-mode ultrasonography. 
IMT values between 0.9 and 1.3 mm were defined "thickening" and those 
higher than 1.3 mm as "plaque".  
Chronic kidney disease was assessed by Glomerular filtration rate (GFR) 
using the simplified MDRD formula[139] and involvement was quantify as 
grade 1 to 3.  The patients were stratified by the glomerular filtration rate 
(GFR) in three groups:  Group 1: increased or normal GFR (GFR≥90 
mL/min/1.73 m
2
); Group 2: mild GFR (60<GFR<90 mL/min/1.73 m
2
);  
Group 3: moderate and severe GFR (GFR≤60 mL/min/1.73 m2)[140]. 
4.2.6 Processing 24-Hour Holter Recordings 
On 2 consecutive days, patients underwent 24-hour ambulatory BP 
monitoring, 24-hour ECG Holter recording. The recorders were applied 
between 9 and 11 AM on a working day, and patients were asked to follow 
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as closely as possible their usual daily activities during each monitoring 
session. They were asked to stay in bed from 11 PM to 7 AM, and all 
reported to have slept normally during the nights they were monitored.  
The series of normal to normal (NN) beat intervals were obtained from 
ECG recordings using OSAS, an open-source software for QRS detection 
and beat classification[141].  
Standard long-term HRV analysis on nominal 24-h recordings according to 
International Guidelines was performed [113].  
The HRV analysis was performed using PhysioNet's HRV Toolkit[112]. 
The NN/RR ratio was computed as the fraction of total RR intervals 
classified as normal-to-normal (NN) intervals. This ratio has been used as a 
measure of data reliability, excluding records with a ratio less than a 
threshold. The authors chose a threshold of 80%, as it was a satisfactory 
trade-off between numbers of included subjects and quality of NN signals. 
All the computed basic time- and frequency-domain HRV measures were 
widely used in the literature[113]  
A number of standard statistical time-domain HRV measures are 
calculated: Average of all NN intervals (AVNN), standard deviation of all 
NN intervals (SDNN), standard deviation of the averages of NN intervals 
in all 5-min segments of a 24-h recording (SDANN), mean of the standard 
deviations of NN intervals in all 5-min segments of a 24-h recording 
(SDNN IDX), square root of the mean of the sum of the squares of 
differences between adjacent NN intervals (RMSSD), percentage of 
differences between adjacent NN intervals that are longer than 50 ms 
(pNN50). 
The frequency-domain HRV measures rely on the estimation of power 
spectral density (PSD) computed, in this work, by Lomb-Scamble 
periodogram [118] 
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After PSD estimation, six standard frequency-domain HRV measures were 
calculated: total spectral power of all NN intervals up to 0.4 Hz 
(TOTPWR), between 0 and 0.003 Hz (ULF), between 0.003 and 0.04 Hz 
(VLF), between 0.04 and 0.15 Hz (LF), and between 0.15 and 0.4 Hz (HF), 
ratio of low to high frequency power (LF/HF).  
4.2.7 Statistical Analysis  
Data were analysed by the use of PASW software (version 18; SPSS, 
Chicago, IL, USA).  
Univariate differences were analysed using Kruskal-Wallis test for HRV 
measures, ANOVA for the other continuous variables (for instance age, 
IMT, etc) and χ test for the categorical variables (for instance sex, 
smoking). For each HRV measure, which differs significantly among the 
three groups, an adjusted model was proposed by performing a multinomial 
logistic regression. For each factor, the coefficient of the estimated 
regression model (β), the confidence interval for β at 95% and the 
corresponding statistical significance (p) are presented. 
4.3 Results 
200 patients were analysed (127 male and 73 female). Demographic, 
clinical and laboratory characteristics of all the study population are shown 
in Table 11. The prevalence of diabetes in our study population was 18%. 
These patients were treated with anti-diabetic drugs (insulin, sulfonylureas, 
thiazolidinediones). 
 
Table 11: Characteristics of the study sample of patients 
Variables Values 
Age (years) 62.4±12 
IMT  2.24±1.56 
LVMIDP 130.2±30.8 
MDRD 77.3±18.5 
 90 
Variables Values 
Diastolic BP (mmHg) 75.6±11.9 
Systolic BP (mmHg) 133±22.6 
Pulse pressare (mmHg) 57.5±17.8 
Fasting blood glucose (mmHg) 102.9±24 
Total Cholesterol (mg/dl) 186±40.5 
Sex (male/female, %) 63.5/46.5 
Diabetes (yes / no, %) 18 / 82 
Fam Hypertension (yes/no, %) 57/43 
Fam. Ictus (yes/no, %) 18/82 
Smokers (yes/ex/no, %) 18/21/62 
Beta-blockers(yes/no, %) 33.5/66.5 
Alfabeta-blockers (yes/no, %) 10/90 
Alpha-blockers (yes/no, %) 8/92 
Diuretics (yes/no, %) 43/57 
ACE-inhibitor (yes/no, %) 37/63 
Dihydropyridine (yes/no, %) 26/74 
Vascular Involvement (no/ thickening/plague, %) 24/60/76 
Kidney Involvment (Group 1/ 2 /3 %) 13.5/11/86.5 
Left Ventricular hypertrophy (yes/no) 40.5/59.5 
 
Table 12 shows the characteristic of the study sample of patients 
categorized by GFR in three groups. The Group 3 is significantly older than 
the others and has a significantly higher proportion of patients taking 
diuretic. Diastolic Blood Pressure, Systolic Blood Pressure and Pulse 
Pressure values were significantly higher in Group 2, where IMT value 
were significantly lower in Group 1. 
 
Table 12: Characteristics of the study sample of patients stratified by GFR 
Variables Group 1 Group 2 Group 3 p-value 
Age (years) 56±11.4 63±11.6 69.7±9.2 0.000 
IMT  1.8±0.76 2.23±1.21 2.9±2.85 0.008 
LVMIDP 124.3±25.9 132.8±32.1 128.9±30.9 0.263 
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Variables Group 1 Group 2 Group 3 p-value 
MDRD 101.9±11.8 74.3±8.7 51.5±6.2 0.000 
Diastolic BP (mmHg) 73.2±13.8 77.3±11.4 72.6±9.6 0.042 
Systolic BP (mmHg) 124.5±23.1 137.3±19.7 129.5±27 0.002 
Pulse pressare (mmHg) 51.3±14 60±16.8 57±23.2 0.015 
Fasting blood glucose 
(mmHg) 
99.7±31.9 102.9±19.9 107.4±23.5 0.368 
Total Cholesterol 
(mg/dl) 
178.9±36 187.7±40.4 190.3±45.2 0.358 
Sex (male/female, %) 64.6/35.4 64.2/35.8 59.4/40.6 0.868 
Diabetes (yes / no, %) 18.8/81.2 16.7/83.3 21.9/78.1 0.783 
Fam. Hypertension 
(yes/no, %) 
52.1/47.9 58.3/41.7 59.4/40.6 0.728 
Fam. Ictus (yes/no, %) 20.8/79.2 18.3/81.7 12.5/87.5 0.629 
Smokers (yes/ex/no, %) 27.1/16.7/56.2 14.2/22.5/63.3 15.6/18.8/65.6 0.363 
Beta-blockers 
(yes/no, %) 
31.3/68.7 34.2/65.8 34.4/65.6 0.931 
Alfabeta-blockers 
(yes/no, %) 
10.4/89.6 11.7/88.3 3.1/96.9 0.357 
Alpha-blockers(yes/no, 
%) 
6.3/93.7 6.7/93.3 15.6/84.4 0.221 
Diuretics (yes/no, %) 35.4/64.6 40.8/59.2 62.5/37.5 0.042 
ACE-inhibitor (yes/no, %) 33.3/66.7 40/60 31.3/68.7 0.550 
Dihydropyridine  
(yes/no, %) 
25/75 25/75 31.3/68.7 0.761 
Kidney Involvement 
 (Group 1/ 2 /3, %) 
0/0/100 0/100/0 100/0/0 0.000 
Vascular Involvement 
(plague/thickening/no, %) 
68.7/12.5/18.8 75.9/10.8/13.3 84.4/9.4/6.2 0.553 
Left Ventricular 
 hypertrophy (yes/no) 
50/50 62.5/37.5 62.5/37.5 0.306 
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Table 13 shows the mean value of HRV measures in the groups. The three 
groups differed significantly in LF/HF. This difference persisted even in 
the adjusted model, as shown in Table 14. 
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Table 13: Comparisons of HRV measurement  in the group of patients stratified by GFR 
 MDRD>90 90>MDRD>60 MDRD<60   
  
Mean Median Percentiles Mean Median Percentiles Mean Median Percentiles   
25 75 25 75 25 75 p-value 
AVNN 859.656 848.931 784.875 915.911 866.782 852.402 772.551 953.323 890.917 875.997 806.343 963.397 0.358 
SDNN 125.662 119.542 102.303 145.981 119.634 111.134 92.211 141.291 118.098 113.797 98.261 141.068 0.309 
SDANN 113.399 108.585 90.246 137.020 106.970 99.823 78.398 129.377 106.366 105.624 86.031 132.446 0.331 
SDNN IDX 51.926 51.430 43.872 58.769 51.192 47.101 40.778 61.044 46.204 45.040 36.859 58.248 0.244 
RMSSD 32.572 30.060 24.496 37.738 35.615 30.525 22.410 42.082 35.971 33.665 24.671 42.061 0.501 
pNN50 8.825 7.678 3.942 11.742 11.169 7.884 2.732 17.711 11.694 10.063 4.069 12.851 0.661 
TOTPWR 18224.030 16124.350 11012.100 23626.200 17528.314 13783.600 9042.495 21606.800 17473.407 15175.150 10303.480 24712.600 0.355 
ULF 14919.459 12378.550 8864.230 18678.700 14139.891 10707.800 7102.665 18480.050 14610.106 12001.300 8215.475 20216.800 0.359 
VLF 1815.051 1592.025 1195.170 2367.555 1865.617 1421.585 961.295 2404.685 1404.330 1259.530 812.876 1958.985 0.110 
LF 860.764 711.187 485.837 1102.005 822.330 600.558 370.216 916.729 678.619 577.239 373.462 925.431 0.154 
HF 628.760 471.256 298.766 724.492 700.487 493.440 201.829 801.501 780.358 549.748 288.798 1230.165 0.436 
LF/HF 1.741 1.439 1.168 2.099 1.508 1.253 0.910 1.751 1.012 0.867 0.724 1.251 0.000 
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Table 14: Adjusted model for all the variables for the relationship between LF/HF 
and the groups according to MDRD; the group 3 (MDRD < 60) is the reference in 
this model 
 
B 
Error 
std Wald df Sig. Exp(B) 
95% Confidence 
Interval for 
Exp(B) 
Lower 
bound 
Upper 
bound 
1 Intercept 5.856 2.512 5.434 1 .020       
LF/HF .977 .459 4.522 1 .033 2.655 1.079 6.531 
SystolicBP -.005 .011 .213 1 .645 .995 .973 1.017 
Age -.104 .028 14.351 1 .000 .901 .854 .951 
No Hypertensive 
Familiarity 
1.153 .536 4.635 1 .031 3.168 1.109 9.050 
2 Intercept .322 2.225 .021 1 .885 
      
LF/HF .993 .436 5.188 1 .023 2.699 1.149 6.341 
SystolicBP .021 .010 4.226 1 .040 1.021 1.001 1.042 
Age -.051 .024 4.473 1 .034 .950 .906 .996 
No Hypertensive 
Familiarity 
.758 .448 2.862 1 .091 2.134 .887 5.138 
 
Among all the variables, which were considered in the adjusted model, the 
multinomial logistic regression selected age, hypertensive familiarity, and 
systolic blood pressure. Higher values of LF/HF are associated with an 
increased probability that a subject belongs to the Groups 1 or 2 rather than 
to the Group 3 (odd ratio 2.655 and 2.699 respectively). Older age is 
associated with a decreased probability of being in Group 1 or 2 (odd ratio 
0.901 and 0.950 respectively).  No hypertensive familiarity is associated 
with an increased probability of belonging to Group 1 (odd ratio 3.168). 
Higher value of systolic blood seems to be associated with a slightly 
increased probability of belonging to Group 2 (odd ratio 1.021). 
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Table 15 shows the characteristic of the study sample of patients 
categorized by IMT in three groups. The Plague Group is significantly 
older than the others. LVMIDP values were significantly higher in the 
Plague Group and the proportion of patient with LVH was significantly 
higher. A significantly higher proportion of patients with hypertensive 
familiarity was assessed in Thickening Group. A significantly higher 
proportion of patients taking beta-blockers was assessed in the Group with 
no vascular involvement. 
 
Table 15: Characteristics of the study sample of patients stratified by IMT 
Variable 
No Vascular 
Involvement  Thickening Plague 
p-
value 
Age (years) 47.7±13 57±9.4 65.8±9.7 0.000 
IMT  0.9±0.1 1.19±0.08 2.62±1.61 0.000 
LVMIDP 109.5±18.3 126.7±32.4 134.3±30.7 0.000 
MDRD 83.7±16.9 81.2±17.4 75.5±18.6 0.060 
Diastolic BP (mmHg) 76.3±10.4 73.4±18.1 75.7±11 0.663 
Systolic BP (mmHg) 130.9±18.7 124±32.4 134.7±21 0.105 
Pulse pressare (mmHg) 54.6±14.4 50.6±19.4 59±17.8 0.082 
Fasting blood glucose 
(mmHg) 
98.5±20 95.7±21.5 104.7±24.7 0.156 
Total Cholesterol (mg/dl) 182.1±36.6 192±38.2 185.8±41.3 0.691 
Sex (male/female, %) 63/37 45.5/54.5 66.2/33.8 0.167 
Diabetes (yes / no, %) 11.1/88.9 4.5/95.5 21.2/78.8 0.100 
Fam Ipertensione (yes/no, 
%) 
63/37 81.8/18.2 52.3/47.7 0.026 
Fam, Ictus (yes/no, %) 14.8/85.2 31.8/68.2 16.6/83.4 0.197 
Smokers (yes/ex/no, %) 14.8/11.1/74.1 27.3/9.1/63.6 16.6/23.8/59.6 0.235 
Beta-blockers(yes/no, %) 55.6/44.4 27.3/72.7 30.5/69.5 0.032 
Alfabeta-blockers(yes/no, 
%) 
3.7/96.3 13.6/86.4 10.6/89.4 0.456 
Alpha-blockers(yes/no, %) 3.7/96.3 9.1/90.9 8.6/91.4 0.674 
Diuretics (yes/no, %) 33.3/66.7 36.4/63.6 45.7/54.3 0.392 
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Variable 
No Vascular 
Involvement  Thickening Plague 
p-
value 
ACE-inhibitor (yes/no, %) 37/63 36.4/63.6 37.1/62.9 0.998 
Dihydropyridine (yes/no, 
%) 
25.9/74.1 18.2/81.8 27.2/72.8 0.669 
Kidney Involvment (Group 
1/ 2 /3 %) 
7.4/59.3/33.3 13.6/59.1/27.3 17.8/60.3/21.9 0.553 
Vascular Involvement 
(plague/thickening/no, %) 
0/0/100 0/100/0 100/0/0 0.000 
Left Ventricular 
hypertrophy (yes/no) 
22.2/77.8 50/50 67.5/32.5 0.000 
 
Table 16 shows the mean value of HRV measures in the groups. The three 
groups differed significantly in SDNN, SDANN, Total Power, LF, and 
LF/HF. The adjusted models confirmed these difference in the value of 
SDNN and SDANN.  
In fact, as shown by Table 17 and Table 18 higher value of SDNN and 
SDANN are associated with an increased probability that a subject had no 
vascular involvement rather than plague (odd ratio 1.017 in both cases). 
Moreover, these models confirms that older age is associated with a 
vascular involvement. 
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Table 16: Comparisons of HRV measurement  in the group of patients stratified by IMT 
  
No Vascular invovement 
 
Thickening Plague 
  
  
Mean Median Percentiles Mean Median Percentiles Mean Median Percentiles   
25 75 25 75 25 75 p-value 
AVNN 826.684 812.136 747.978 910.820 842.253 820.497 750.911 955.632 880.375 865.860 797.949 952.010 0.074 
SDNN 140.284 133.950 107.341 168.065 121.747 115.265 94.650 145.492 117.224 111.984 93.737 136.941 0.039 
SDANN 129.041 125.517 89.704 155.750 110.781 102.201 82.055 137.995 104.383 99.402 80.588 124.070 0.033 
SDNN IDX 58.381 52.787 44.646 71.452 50.739 48.891 43.382 56.469 49.149 47.437 39.186 59.529 0.060 
RMSSD 36.311 30.926 26.458 41.442 30.737 29.744 22.262 33.683 35.309 30.656 22.703 41.714 0.310 
pNN50 12.132 8.123 5.739 15.845 9.164 6.089 2.860 11.039 10.656 8.439 3.099 15.453 0.300 
TOTPWR 24097.15 19770.90 12982.60 30746.73 17583.21 14497.00 9953.56 21881.20 16555.28 13889.30 9328.20 21254.72 0.043 
ULF 19533.87 16191.40 9760.808 24292.95 14453.19 11822.15 8122.05 18502.50 13477.22 11035.00 7340.168 17850.97 0.074 
VLF 2536.076 2009.720 1123.815 3013.678 1745.842 1513.635 1114.73 1859.600 1649.354 1343.890 960.970 2250.945 0.079 
LF 1237.769 921.762 511.003 1723.410 818.685 687.722 494.334 933.637 730.339 570.636 362.265 934.279 0.009 
HF 789.434 541.702 294.196 1215.156 565.502 499.355 185.849 596.352 698.375 477.522 231.957 913.954 0.485 
LF/HF 1.898 1.556 1.078 2.358 2.019 1.551 1.192 2.685 1.333 1.131 0.826 1.679 0.001 
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Table 17: Adjusted model for all the variables for the relationship between SDNN 
and the groups according to IMT; the Plague Group is the reference in this model 
 
B 
Error 
std Wald df Sig. Exp(B) 
95% Confidence 
Interval for Exp(B) 
Lower 
bound 
Upper 
bound 
1 Intercept 5.580 1.743 10.250 1 .001       
SDNN .017 .007 5.305 1 .021 1.017 1.003 1.032 
Age -.166 .029 32.036 1 .000 .847 .800 .897 
No Hypertensive Familiarity .261 .544 .230 1 .632 1.298 .447 3.774 
2 Intercept 2.534 1.619 2.452 1 .117       
SDNN .008 .007 1.660 1 .198 1.009 .996 1.022 
Age -.083 .025 11.254 1 .001 .920 .876 .966 
No Hypertensive Familiarity -1.100 .592 3.454 1 .063 .333 .104 1.062 
 
Table 18: Adjusted model for all the variables for the relationship between SDNN 
and the groups according to IMT; the Plague Group is the reference in this model 
  
B 
Error 
std Wald df Sig. Exp(B) 
95% Confidence 
Interval for 
Exp(B) 
Lower 
bound 
Upper 
bound 
1 Intercept 5.763 1.696 11.548 1 .001       
SDANN .017 .007 5.824 1 .016 1.017 1.003 1.031 
Age -.166 .029 32.107 1 .000 .847 .800 .897 
No Hypertensive Familiarity .277 .547 .257 1 .612 1.320 .452 3.857 
2 Intercept 2.492 1.586 2.467 1 .116       
SDANN .010 .006 2.219 1 .136 1.010 .997 1.023 
Age -.083 .025 11.227 1 .001 .920 .876 .966 
No Hypertensive Familiarity -1.082 .593 3.325 1 .068 .339 .106 1.084 
 
Table 19 shows the characteristic of the study sample of patients with and 
without LVH. The LVH Group is significantly older than the other. IMT 
values were significantly higher in the LVH Group and the proportion of 
patient with Vascular Involvement was significantly higher. A significantly 
higher proportion of patients taking diuretics and patients suffering from 
 99 
diabetes was assessed in LVH Group. The value of SBP and PP were 
significantly higher in the VLH group. 
Table 19: Characteristics of the study sample of patients with and without LVH 
 No VLH VLH  
Age (years) 56.9±11.9 66.1±10.5 0.000 
IMT  1.81±0.92 2.52±1.81 0.000 
LVMIDP 105±13.6 147.3±27.2 0.000 
MDRD 79.8±17.7 75.5±18.8 0.071 
Diastolic BP (mmHg) 73.8±11.9 76.7±11.8 0.221 
Systolic BP (mmHg) 126±25 137.7±19.3 0.001 
Pulse pressare (mmHg) 52.2±17.8 61.1±16.8 0.002 
Fasting blood glucose (mmHg) 99.9±23.4 104.8±24.2 0.055 
Total Cholesterol (mg/dl) 191±38.1 182.6±41.6 0.175 
Sex (male/female, %) 61.7/38.3 64.7/35.3 0.668 
Diabetes (yes / no, %) 9.9/90.1 23.5/76.5 0.014 
Fam Ipertensione (yes/no, %) 60.5/39.5 54.6/45.4 0.410 
Fam. Ictus (yes/no, %) 18.5/81.5 17.6/82.4 0.875 
Smokers (yes/ex/no, %) 21/22.2/56.8 15.2/19.3/65.5 0.419 
Beta-blockers(yes/no, %) 38.3/61.7 30.3/69.7 0.238 
Alfabeta-blockers(yes/no, %) 8.6/91.4 10.9/89.1 0.597 
Alpha-blockers(yes/no, %) 6.2/93.8 9.2/90.8 0.432 
Diuretics (yes/no, %) 30.9/69.1 51.3/48.7 0.004 
ACE-inhibitor (yes/no, %) 30.9/69.1 41.2/58.8 0.138 
Dihydropyridine (yes/no, %) 21/79 29.4/70.6 0.182 
Kidney Involvment  
(Group 3/ 2 /1 %) 
14.8/55.6/29.6 16.8/63/20.2 0.306 
Vascular Involvement 
(plague/thickening/no, %) 
60.5/13.6/25.9 85.8/9.2/5 0.000 
Left Ventricular hypertrophy 
(yes/no) 
0/100 100/0 0.000 
 
Table 20 shows the comparison of HRV measures in the patients with and 
without VLH.  The two groups differed significantly in AVNN and LF/HF. 
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The adjusted model, such as the one reported in Table 21, did not confirm 
these difference, and showed that other variable were associated with VLH 
such as Age, Systolic Blood Pressure, Cholesterol, and Diuretics 
assumption. 
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Table 20: Comparisons of HRV measurement in the group of patients with and without LVH 
  
No LVH 
 
LVH 
  
  
Mean Median Percentiles Mean Median Percentiles   
25 75 25 75 P Value 
AVNN 845,595 827,887 772,150 915,004 884,819 867,100 791,728 963,805 0,046 
SDNN 123,743 118,484 101,663 143,219 118,856 113,243 92,795 142,407 0,253 
SDANN 111,605 107,254 88,133 131,307 106,245 99,402 80,050 129,532 0,292 
SDNN 
IDX 51,820 49,334 43,116 60,694 49,719 48,334 38,678 58,396 0,162 
RMSSD 32,613 29,032 22,774 36,409 36,527 32,875 23,345 42,254 0,087 
pNN50 9,808 6,961 3,037 11,751 11,292 9,214 3,391 17,050 0,125 
TOTPWR 18505,554 16012,800 10952,300 21896,700 17128,994 14063,700 9098,123 22697,050 0,302 
ULF 15068,814 12109,900 8462,103 18527,900 13948,491 11534,400 7132,508 18655,575 0,355 
VLF 1882,325 1659,880 1082,100 2390,558 1709,805 1343,890 938,679 2086,480 0,137 
LF 894,710 711,065 429,249 1090,893 749,921 559,352 371,320 911,662 0,078 
HF 659,714 476,406 205,448 747,982 720,787 504,430 266,741 964,938 0,229 
LF/HF 1,782 1,643 1,038 2,095 1,282 1,040 0,822 1,505 0,000 
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Table 21: Adjusted model for all the variables for the relationship between LF/HF 
and the groups according to LVH; the LVH Group is the reference in this model 
 
B E.S. Wald df Sig. Exp(B) 
95% Confidence 
Interval for Exp(B) 
Lower 
bound 
Lower 
bound 
  LF/HF -.200 .207 .935 1 .334 .819 .546 1.228 
Age .068 .017 15.394 1 .000 1.070 1.035 1.107 
Systolic BP .029 .009 11.260 1 .001 1.030 1.012 1.047 
Cholesterol -.009 .004 4.334 1 .037 .991 .983 .999 
Diuretics -.779 .346 5.081 1 .024 .459 .233 .903 
Intercept -5.240 1.804 8.441 1 .004 .005     
 
4.4 Discussion  
In this study I evaluated in hypertensive patients the effects of complete 
CV involvement on cardiac autonomic control, as assessed by means of 
heart period variability analysis. Power spectral analysis of 24-hour 
electrocardiographic monitoring was performed in 200 hypertensive 
patients in basal conditions. At this same times, patients underwent 24-hour 
blood pressure monitoring, echocardiographic and carotic ultrasonographic 
study evaluations, and routine laboratory evaluations in order to calculate 
VFG with MDRD formula. 
The LF/HF, shown as a marker of the sympatho-vagal balance, decreased 
significantly in the group with organ damage. However, when adjusted 
with the other variable, in particular Age, this difference is significant only 
for Kindney organ damage. SDNN and SDANN, index of the overall heart 
rate modulation, decreased significantly in the group of patients with 
Plague, also when adjusted considering the other variables. 
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5. Long-term survival prediction 
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5.1 Introduction 
Over the last three decades a range of risk factors for mortality among 
community-dwelling people has been identified [142-156]. Understanding 
the factors that increase the risk of mortality may be promoting survival, as 
well as helpful in promoting health and well-being, in later life. The 
majority of previous studies on mortality were performed using 
conventional statistical techniques, for example, regression analysis, in 
order to identify factors that increase, or decrease, the risk of mortality 
[157]. For reasons of statistical power and computational complexity, 
conventional statistical techniques enables only a limited number of 
potential risk factors to be examined [157]. Some recent studies have 
applied data-mining techniques, in particular, in a previous study [158] a 
genetic algorithm and Cox regression were combined to identify risk 
factors among a wide number of variables.  
The aim of this study was to develop a CART model which can predict 15 
year survival with acceptable sensitivity and specificity in order to provide 
further knowledge about previously identified risk factors. 
5.2 Methods and materials 
Data were derived from the Nottingham Longitudinal Study of Activity and 
Ageing (NLSAA)[159]. NLSSA is an ongoing survey of activity, health 
and well-being conducted within a representative sample of 1299 
community-dwelling people originally aged 65 and over, of whom 1042 
(406 men; 636 women) agreed to participate (response rate = 80 %). The 
baseline survey was conducted between May and September 1985, and 
information on mortality within the sample was provided by the UK 
National Health Service Central Register, where all UK deaths are recorded 
and which supplied copies of all the death certificates as they accrued. 
Interview data collected from respondents included information on 
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cognition, physical health, psychological wellbeing, perceptions of health 
and wellbeing, and customary physical activity, and are described in detail 
elsewhere[159]. 
I considered the set of variables which were identified in [158] as 
predictors of long-term mortality. In this previous study [158], genetic 
algorithms were used to select the combination of variables that maximized 
the goodness of fit for the Cox regression model. Table 21 and Table 22 
show the selected continuous and categorical variables, respectively. 
 
Table 22: Descriptives of continuous variables identified as Risk Factors for 15-
Year Mortality among community-dwelling older people [158]. 
Continuous Variables Range Mean Median 
Age at 85 interview (computed from borndate) 65-99 75.63 75 
Number of living great-grandchildren 0-26 1.12 0 
Dose of hypnotic drug being taken (mg) 0-1300 28.08 0 
Hypnotic drug taken for (n) years 0-47 1.46 0 
Maximum handgrip strength 43-617 254.75 237 
Maximum handgrip strength for dominant hand 29-612 246.43 231 
Maximum handgrip strength for non-dominant 
hand 
27-617 235.20 220 
Right Handgrip strength at first measurement(kg) 2-57 23.25 22 
Right Handgrip strength at third measurement(kg) 3-63 25.33 24 
Left Handgrip strength at third measurement (N)  22-556 222.73 208 
Number of floors in accommodation 1-3 1.67 2 
 
I developed a binary classifier based on CART [160] in order to predict 15-
year mortality. The information on mortality within the sample was 
provided by the UK National Health Service Central Register and for the 
purpose of this study were update to 2000, 15 years after the baseline 
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survey (1985). The values of the input variables, summarized in Table 22 
and Table 23, were collected in the baseline survey conducted in 1985. 
 
Table 23: Descriptives of categorical variables identified as Risk Factors for 15-
Year Mortality among community-dwelling older people [158] 
Categorical Variables Category N % 
Permission to access OPCS (Office for Census 
and Population Studies) files? 
Yes, permission given 1,022 98 
No, permission refused 20 2 
Activity compared with that of age group 1- Much more active 125 13 
2- More active 398 41 
3- About as active 225 23 
4- Less active 154 16 
5- Much less active 59 6 
How much happiness in your life today? A lot 322 33 
Quite a lot 230 24 
A little 238 24 
None 184 19 
Joint pain causing difficulty in carrying bags? No difficulty 783 83 
Yes, difficult 160 17 
Joint pain causing difficulty in walking? No difficulty 691 69 
Yes, difficult 306 31 
Ability to raise £200 in an emergency No difficulty 714 71 
A Little Difficulty 121 12 
A Lot of Difficulty 102 10 
Impossible to raise 73 7 
Time since last visited the dentist Last week 18 2 
Last month 34 3 
Within last six months 89 9 
> 6 months ago 876 86 
Time since last visited the optician Last week 18 2 
Last month 30 3 
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Categorical Variables Category N % 
Within last six months 164 16 
> 6 months ago 805 79 
Time since last visited the social worker Last week 7 1 
Last month 18 2 
Within last six months 31 3 
> 6 months ago 959 94 
Reported stomach troubles? No problem 748 73 
Yes, problem 283 27 
Reported pain in left anterior chest? No 959 98 
Yes 18 2 
Reported chest pain in no specific position? No 968 99 
Yes 9 1 
 
In order to optimize the tree performance, an a priori classification cost 
could be assigned. I examined different misclassification cost ratios c(1|2)/ 
c(2|1):  1/1, 1.5/1, 2/1, 2.5/1. For instance, a misclassification cost ratio of 
2/1 means that the cost of misclassifying a survivor was twice as great as 
that of misclassifying a participant who had died. Stopping rules govern the 
size of the tree.  
The misclassification risks are estimated by 10-fold cross-validation 
methods. The cross-validation method consists of dividing the sample into 
a number of folds and generating tree models excluding the data from each 
fold in turn. For each model, the misclassification risk is estimated by 
applying the tree to the fold excluded in generating it. The risk estimate for 
the final tree is calculated as the average of the risks for all of the 
trees[160]. 
The performance of each classifier against the whole dataset is assessed 
using the common measures for binary classification, calculated as reported 
 108 
in Table 24. I selected the classifiers with a high sensitivity value (higher 
than 75%) and acceptable specificity values (higher than 65%). 
 
Table 24: Performance Measurement 
Measure Abbreviation formula 
Accuracy ACC 
FNFPTNTP
TNTP


 
Sensitivity SEN 
FNTP
TP

 
Specificity SPE 
TNFP
TN

 
Positive predictive 
value 
PPV 
FPTP
TP
  
Negative predictive 
value 
NPV ;
FNTN
TN
  
Where: 
TP (true positives) is the number of survivors, correctly classified by the system,  
TN (true negatives) is the number of participants who have died, correctly classified by 
the system,  
FP (false positives) is the number of participants who have died, incorrectly labelled as 
survival by the system,  
FN (false negatives) is the number of survivors, incorrectly 
5.3 Results 
The performance measurement, including risk estimation and confusion 
matrix values, for the developed classifier which achieved the best 
performance are summarized in Table 25.  
 
Table 25: performance of the selected model 
Cost 
Ratio 
Alive Dead Risk      
TP FN TN FP Estimate Error Acc Sen Spec PPV NPV 
2.5:1 235 73 487 247 0.517 0.023 69.3% 76.3% 66.3% 48.8% 87.0% 
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The model considers age, permission given to access OPCS file, dose of 
Figure 17: selected model for long-term survival prediction 
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total prescribed drugs, the maximum grip for both hands, and right 
handgrip strength. The initial variable selected by CART  was age (with a 
cut-off of 77.291), people older than 77.291 year were classified as not 
surviving.  
CART selected Permission to access OPCS (Office for Census and 
Population Studies) files in node 2 splitting: people who refused this 
permission were predicted to survive, the others were split according to the 
dose of total prescribed drug being taken, if it was not more than 1.00 mg, 
they were predicted to survive, otherwise they were classified according to 
their handgrip strength and age. 
5.4 Discussion 
This study integrated the results of the previous research [157, 158] which 
used Cox regression combined with Genetic Algorithms (CoRGA) to 
identify risk factors for long-term mortality among older people. The 
CART analysis was performed in order to improve the knowledge about 
the importance of the identified factor as a predictor of mortality. 
Moreover, using the CART analysis, I observed the range of risk factor 
values which are associated with decreased or increased 15-year-mortality. 
I observed that: 
Being aged more than 77.291 was associated with increased mortality; 
in people aged 65-72 taking drugs / medication of less than 1 mg is 
associated with decreased mortality, 
In people aged 65-72 who took a dose of drug higher than 1 mg, an 
increased or decreased mortality would appear to be associated with the 
interaction of three factors: age, maximum grip strength for both hand and 
right handgrip strength: a higher value of maximum handgrip for both 
hands (>305.500 N) and  younger age (<69.641 years) are associated with 
decreased mortality, while lower values of maximum handgrip strength for 
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both hands, and of right handgrip in conjunction with old age (>70.968) are 
associated with increased mortality. 
First, I compare the result of this research with the previous work of 
Ahamad and Bath [157, 158]. All the variables selected by CART in the 
best models are significant risk factors for increased or decreased 15-year 
mortality in unadjusted models. The CART exclusion of some previously 
identified factors may be explained by the fact that not only are they less 
important but also that Genetic Algorithms and Cox regression may select 
them only because of inner limitations of these techniques. In particular, 
with Genetic Algorithms the number of variables in the final model was 
decided a priori. 
The selection of age as the initial splitting variable provides further 
evidence that this may be the most important factor affecting mortality in 
older people[142, 144, 147]. The selection of handgrip strength in the 
proposed models confirm its importance as predictor of mortality, that has 
been shown by other research [150-154]. The association of decreased 
handgrip strength with increased mortality was probably indicative of 
frailty[155].  
The selection of the total prescribed medication confirms its association 
with mortality, showed by other study[156] 
Refusing permission to access the OCPS file seems to be protective in 
reducing mortality risk: this is due to the fact that almost all people (19 out 
20) who refused permission survived. I believed that this variable is not of 
interest. 
5.5 Conclusion 
I performed a CART analysis on risk factors previously identified using 
Genetic algorithms and Cox regression in order to predict long-term 
survival among older people. CART offers an opportunity to understand 
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the importance of the identified factors as predictors for mortality. The best 
model achieved a sensitivity of  76.3% and a specificity of 66.3%. The 
selection of variables are consistent with previous research [16,17]. In 
particular, age and handgrip strength are the most important variables 
associated with mortality in this study. Furthermore, and what is novel 
regarding this research is that I identified the pivotal values of the risk 
factor or of their combinations associated with increased or decreased 
mortality. 
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